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ABSTRACT 
Objective: Although impaired general intellectual ability is a prevalent feature in schizophrenia, 
patterns suggesting preserved, deteriorated, and premorbidly impaired intellect have also been 
identified. The main purpose of this investigation was to examine the clinical, cognitive, and 
neuroanatomical characteristics of these intellectual subtypes, and to establish the value and 
validity of this approach for reducing the heterogeneity of schizophrenia. Methods: A total of 71 
patients with a diagnosis of schizophrenia or schizoaffective disorder and 66 healthy controls 
were assessed. A ‘preserved’ performance pattern (n=29) was defined by average-range 
estimated premorbid and current IQ with no evidence of decline (premorbid- current IQ 
difference <10 points). A ‘deteriorated’ pattern (n=14) was defined by a difference between 
estimated premorbid and current IQ estimates of 10 points or more. A ‘premorbidly impaired’ 
pattern (n=14) was defined by below average estimated premorbid and current IQ and no 
evidence of decline greater than 10 points. The groups were compared on demographic, 
neurocognitive, clinical, and neuroanatomical variables. Results: Patients with the preserved 
pattern outperformed those meeting criteria for deteriorated and premorbidly impaired 
intellectual ability on a composite measure of neurocognitive ability, as well as on indicators of 
processing speed, attention, working memory, verbal and visual memory, and social cognition. 
However, preserved patients scored lower than control participants on tests of processing speed, 
verbal memory, and reasoning/problem solving. Patients demonstrating the deteriorated and 
premorbidly impaired patterns were indistinguishable across all cognitive measures. The patient 
groups were clinically indistinguishable from each other and showed a similar pattern of 
widespread cortical thinning compared to controls. Conclusions: Cognitive impairment is a core 
feature of schizophrenia present to some degree in all patients, regardless of their intellectual 
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status. Therefore, IQ fails to capture the true breadth of cognitive impairment in schizophrenia. 
Although the preserved subtype has partial validation, comprehensive neurocognitive data 
provides little support for the distinctiveness of deteriorative relative to premorbid intellectual 
compromise. Cognitive ability and symptom severity represent independent disease processes in 
schizophrenia, and cortical thinning across the brain appears to reflect a shared disease process 
with no association to intellectual or cognitive status. 
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Preserved, Deteriorated, and Premorbidly Impaired Patterns of 
 
Intellectual Ability in Schizophrenia 
Introduction 
Schizophrenia is a complex and heterogeneous syndrome characterized by strange and 
questionable beliefs, a profound disruption in emotion and sensory experiences, and a broad 
range of unusual behaviours.  Patients often experience delusions and hallucinations, 
disorganized behaviour, social withdrawal, loss of interest, and reduced motivation (Andreasen 
& Flaum, 1991). Many also experience general distress, depression, and anxiety (Buckley, 
Miller, Lehrer, & Castle, 2009). Schizophrenia is arguably the most disturbing, puzzling, and 
stigmatized of all psychological disorders, with a lifetime prevalence of approximately 1% 
(Government of Canada, 2006; Jablensky, 2000). It is also one of the most debilitating disorders, 
constituting the fifth leading cause of disability in developed countries worldwide, according to 
the World Health Organization (Murray & Lopez, 1997). In fact, when both clinical and 
social/functional dimensions are considered, research shows that only 1 in 7 individuals with 
schizophrenia ‘recover’ and that recovery rates have not increased in recent decades despite 
substantial enhancements in treatment options (Jaaskelainen et al., 2013). This serious condition 
carries a heavy financial burden estimated to be $6.85 billion in Canada in 2004, including health 
care expenditures and lost productivity due to early morbidity and mortality (Goeree et al., 
2005). Indeed, the majority of patients are unemployed, and they are over-represented in prisons, 
homeless shelters, and socially disadvantaged populations (Bellack et al., 2007).  
Heterogeneity in Schizophrenia 
Despite decades of scientific research implicating schizophrenia as a neuropsychiatric 
disease, the etiology, neuropathology, and neuropathophysiology of the illness remain largely 
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unknown. Many have argued that this is in part due to the extensive heterogeneity observed in 
people with the illness. Indeed, it has been suggested that this illness is best understood not as a 
single disease entity with pleiotropic manifestations, but rather as a heterogeneous collection of 
pathogenetically distinct subtypes that have been amalgamated and investigated as a single 
diagnostic category (Basso, Nasrallah, Olson, & Bornstein, 1998; Bellak, 1994; Carpenter, 
Buchanan, Kirkpatrick, Tamminga, & Wood, 1993; Gottesman & Gould, 2003; Heinrichs, 2004; 
Jablensky, 2006). In fact, in his seminal work, Bleuler (1911) coined the term “schizophrenia” to 
replace “dementia praecox” and emphasized that it “is not a disease in the strict sense, but 
appears to be a group of diseases…Therefore we should speak of schizophrenias in the plural.” 
The heterogeneity in schizophrenia involves widespread variability in symptom 
expression, course, neurocognitive function, functional outcome, and biological findings. The 
symptoms of schizophrenia span a broad array of psychopathology and exhibit a remarkable 
amount of interindividual variability and temporal inconsistency. In addition, the onset of 
symptoms may be insidious in nature or rather abrupt. Cognitive deficits in schizophrenia are 
heterogeneous as well, ranging from persistent generalized impairment to slight focal deficits or 
virtually average or even superior performance. Further, although the idea of functional decline 
as a diagnostic hallmark of schizophrenia is reflected in current classifications and diagnostic 
criteria such as the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; American 
Psychiatric Association, 2013), functional impairments are not universal. In fact, the functional 
status of patients can range from near normal to severe dependency and disability. Schizophrenia 
is also probably biologically heterogeneous and resists reduction to well-characterized causal 
mechanisms and pathologies. Genetic linkage and association studies have targeted multiple 
candidate loci and genes, but rejected the parsimonious hypothesis that all schizophrenia is 
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caused by the same pattern of genetic mutations, brain dysmorphology and neurochemical 
abnormalities (Jablensky, 2006). It appears that schizophrenia has a multifarious neurobiology 
with various genes, gene interactions, and epigenetic effects influencing risk. Accordingly, well-
characterized causal mechanisms and pathologies are far from being established (Bray, 2008; 
Maric & Svrakic, 2012; Rees, O’Donovan, & Owen, 2015). It has been argued that such inherent 
phenotypic variation indicates etiologic heterogeneity, and raises questions about the ability of 
the broad clinical category of schizophrenia to establish biologically homogeneous populations 
for genetic etiological research. Therefore, one can argue that the phenotypic variability in 
schizophrenia has been the principal barrier in the search for the causes of this devastating 
illness.  
Subtyping Schizophrenia 
To address this heterogeneity, numerous attempts have been undertaken to develop 
schemas to organize the illness and identify more homogeneous groups of patients with similar 
illness presentations within the schizophrenia patient population. Attempts to organize the 
complexity of the broad clinical definition of schizophrenia into simpler component disorders or 
subtypes have been made since the delineation of the diagnostic category, using clinical, 
behavioural, or biological criteria, as well as a variety of statistical methods such as factor and 
cluster analysis. Subtypes based on putative genetic indicators such as a positive family history 
for schizophrenia spectrum disorders have also been proposed (Lewis, Reveley, Reveley, 
Chitkara, & Murray, 1987). It has been argued that, ultimately, these subtypes may map onto 
parallel pathophysiologies, etiologies, and treatment approaches (Vaz & Heinrichs, 2006). The 
ultimate hope is that the aggregate label of ‘schizophrenia’ will one day be substituted by a 
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number of more accurate diagnoses based on distinct underlying etiologies and 
pathophysiologies.  
Symptomatic Subtyping  
The traditional approach to subtyping schizophrenia has involved the use of individual 
symptoms or clusters of symptoms to establish typologies and subclassifications (e.g., American 
Psychiatric Association, 1994; Crow, 1980; Hill, Ragland, Gur, & Gur, 2001; Morrison, Bellack, 
Wixted, & Mueser, 1990; Nicholson & Neufeld, 1993). Crow
 
(1980) put forth a basic 
subclassification of schizophrenia, based on the prevalence of either positive or negative 
symptoms. 'Type I' (positive) schizophrenia was distinguished by a clinical profile characterized 
by hallucinations, delusions, and formal thought disorder, while patients with 'Type II' (negative) 
schizophrenia presented with social withdrawal, loss of volition, restricted affect, and poverty of 
thought, action, and speech. It was hypothesized that each illness variant has a unique treatment 
response because each reflects a distinct underlying biology and disease process. Dopaminergic 
dysfunction was presumed to underlie 'Type I' schizophrenia, while structural brain 
abnormalities were thought to underlie 'Type II’ schizophrenia. Patients have also been classified 
into deficit and nondeficit schizophrenia, paranoid and non-paranoid subtypes among others 
(American Psychiatric Association, 1994; Kirkpatrick, Buchanan, Breier, & Carpenter, 1993). 
‘Deficit schizophrenia’ is distinguished by persistent ‘primary’ negative symptoms, and is 
associated with reduced rates of paranoid ideation and depression, severe anhedonia, poor social 
functioning, resistance to treatment, and a higher risk of schizophrenia in relatives (Kirkpatrick, 
Ross, Walsh, Karkowski, & Kendler, 2000).  There is evidence for the neuropsychological and 
neurobiological validity of the deficit syndrome as a distinct subtype, but no evidence thus far of 
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a specific genetic profile (Buchanan et al., 1994; Cohen, Forbes, Mann, & Blanchard, 2006; 
Jablensky, 2006; Rowland et al., 2009; Wonodi et al., 2006).  
Although partially successful, these symptom typologies have not met the complementary 
challenges of demonstrating clinical and biological validity and trait-like temporal stability. In 
fact, most attempts at symptomatic subtyping have produced vague boundaries between 
subtypes, weak construct validity, and little diagnostic subtype temporal stability (Carpenter, 
Heinrichs, & Wagman, 1985; Helmes, 1991; Marneros, Deister, & Rohde, 1992). For example, 
while relatively stable over time and psychophysiologically distinct, the paranoid subtype 
overlaps symptomatically with psychotic mood disorder and is neuropsychologically 
indistinguishable from non-paranoid schizophrenia (Jeon & Polich, 2003; Lake, 2008; 
McGlashan & Fenton, 1991). Heinrichs and Awad (1993) argued that subtyping resulting from 
symptom ratings was lacking because the ratings reflect subjective judgment, fluctuate over time, 
and may be difficult to link up directly to neural mechanisms, making symptoms unsuitable for 
use as subtype demarcations in the search for the cause of schizophrenia. Furthermore, 
symptomatic variance accounts for only moderate amounts of variance in functionality (Green, 
1996). This suggests that alternative methods of dividing and organizing schizophrenia into 
distinct component syndromes should be utilized.  
Cognitive Subtyping  
To address the problems of objectivity and stability and afford an alternative to 
symptomatic subtyping, researchers have suggested that subtyping procedures should include 
cognitive variables, with patients grouped according to neuropsychological profiles (Goldstein, 
1994; Goldstein, Allen, & Seaton, 1998; Heinrichs, 2001; Palmer et al., 1997; Paulsen et al., 
1995). In fact, going back to the inception of the diagnostic category at the turn of the 20
th
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century, Kraepelin (1909) asserted that dementia praecox is a cognitive disorder accompanied by 
delusions and hallucinations, but fundamentally typified by “weakening of the mainsprings of 
volition,” “lowered mental efficiency,” “unsteadiness of attention,” “inability to sift, arrange and 
correct ideas, and to accomplish mental grouping of ideas.” In his seminal accounts of dementia 
praecox, Bleuler (1943, 1950) reasoned that deficits in “associative” thinking were 
“fundamental” aberrations in schizophrenia, while clinical symptoms such as delusions and 
hallucinations were only “accessory” (see Sharma & Harvey, 2000, for a review).  
Indeed, it is now generally accepted that cognitive deficits, while heterogeneous in their 
own right, are core and enduring features of schizophrenia (Heinrichs, 2005; Schaefer, 
Giangrande, Weinberger, & Dickinson, 2013). Research in the last three decades has consistently 
established that a majority of patients with schizophrenia perform approximately 1.0 standard 
deviation below healthy people on multiple and diverse clinical neuropsychological measures 
(Dickinson, Ramsey, & Gold, 2007; Heinrichs, 2005; Keefe & Fenton, 2007). A recent large 
review and meta-analysis of cognitive studies from around the world, spanning several decades, 
found that patients with schizophrenia exhibit a generalized cognitive impairment, demonstrating 
that this finding has remained robust over time despite changes in assessment instruments and 
alterations in diagnostic criteria, and that it manifests similarly in different regions of the world 
despite linguistic and cultural difference (Schaefer, Giangrande, Weinberger, & Dickinson, 
2013). Indeed, impairments in neuropsychological abilities are widespread and include working 
memory, attention, verbal learning and memory, visual learning and memory, language, 
reasoning and problem solving, speed of processing, executive function, social cognition, and in 
general intellectual ability (Aleman, Hijman, de Haan, & Khan, 1999; Berna et al., 2011; 
Dickinson et al., 2007; Elvevag & Goldberg, 2000; Green, Kern, & Heaton, 2004; Heinrichs, 
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2005; Heinrichs & Zakzanis, 1998; Lee & Park, 2005; Matza et al., 2006; Reichenberg & 
Harvey, 2007; Zakzanis, Troyer, Rich, & Heinrichs, 2000). In fact, in has been suggested that 
schizophrenia “manifests itself primarily in cognition” (Heinrichs, 2005). Furthermore, it appears 
that the degree of impairment across these cognitive domains is greatly interconnected. 
Dickinson and colleagues (2008) used structural equation modeling to show that approximately 
64% of the variance in neuropsychological performance between schizophrenia patients and 
healthy control participants can be accounted for by a generalized deficit factor. 
Advantages of Cognitive Subtyping 
Neuropsychological test data offer several advantages over symptom ratings as criteria 
for subtyping procedures. Neurocognitive deficits are considered the most stable aspect of 
schizophrenia, with test-retest coefficients ranging from 0.70 to 0.85 (Albus et al., 2002; Bozikas 
& Andreou, 2011; Censits, Ragland, Gur, & Gur, 1997; Hoff et al., 1999). The stability of these 
deficits has been established in numerous studies. For example, cross-sectional studies reveal 
equivalence in the cognitive functioning of young patients with a short duration of illness, old 
patients with a short duration of illness, and old patients with a long duration of illness (Heaton 
et al., 1994; Jeste et al., 1995). In addition, there are no differences in cognitive performance 
between adolescent or first episode patients and chronic patients (Albus et al., 1996; Hoff, 
Riordan, O’Donnell, Morris, & DeLisi, 1992); and no significant differences between age groups 
(Hyde et al., 1994). The preponderance of evidence thus supports the notion of stability in most 
cognitive impairments.  
In addition, neurocognitive performance is more objective and trait-like than symptom 
ratings, with potentially more direct ties to neurobiology and genetics. The latter reflects the field 
of neuropsychology’s long history of research and extensive knowledge base on the 
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neurobiological basis of cognition (Gottesman & Gould, 2003; Heinrichs, 2004, 2005; Strauss & 
Sommerfeldt, 1994), which can be exploited in the pursuit of novel taxonomies for 
schizophrenia. In fact, there is evidence that performance on neurocognitive tests may be 
valuable in organizing the illness into more biologically homogeneous variants and subgroups 
(Heinrichs, 2005).  For instance, schizophrenia patients with and without global cognitive 
impairment have distinct genetic profiles linked to susceptibility genes on chromosome 6, which 
in turn supports the idea that they represent true subtypes in schizophrenia (Hallmayer et al., 
2005; Toulopoulou, Morris, Rabe-Hesketh, & Murray, 2003).  In addition, differences in 
neurocognitive performance between patients with schizophrenia and healthy controls have 
emerged systematically as the most robust findings evidenced by significantly larger effect sizes 
when compared to the neuroimaging domain (Heinrichs, 2005). Altogether, these findings 
provide substantial support for taking a neurocognitive approach to the challenge of 
schizophrenia subtyping. Such subtypes promise to advance both understanding of the disease 
and the development of tailored treatment for persons with schizophrenia. This may be 
particularly so for the genetics of schizophrenia in which the development of cognitive subtypes 
looms as potential endophenotypes, which are features present in individuals with genetic 
variants of risk that could be assessable prior to the manifestation of the clinical symptoms 
(Gottesman & Gould, 2003). The endophenotypes would theoretically be more closely 
associated with the genetic variants of susceptibility of schizophrenia than the clinical 
phenotypes and their use could enhance the predictive power of the groups and afford better 
understanding of both disease pathophysiology and treatment outcome (Gottesman & Gould, 
2003; Jablensky, 2006; Joyce & Roiser, 2007). 
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Finally, cognitive impairments consistently emerge as predictors or mediators and 
possibly even determinants of patients’ ability to function independently in the community 
irrespective of clinical symptom severity (Bowie et al., 2008; Bowie & Harvey, 2005; Bowie, 
Reichenberg, Patterson, Heaton, & Harvey, 2006; Green et al., 2004; Keefe, Poe, Walker, & 
Harvey, 2006; Matza et al., 2006; Milev, Ho, Arndt, & Andreasen, 2005; Mohamed et al., 2008). 
Indeed, it has been argued that as much as 60% of the variance in real world outcome can be 
accounted for by cognitive ability (Green, Kern, Braff, & Mintz, 2000; Green et al., 2004), 
although more recent work has shown that the relationship between cognition and functional 
outcome is actually much more modest, with only 4% to 23% of functional outcome variance 
credited to cognitive performance (Fett et al., 2011). Nevertheless, the consistency of this 
association and the need to improve the functional outcome status of individuals with 
schizophrenia has prompted the introduction of different treatment initiatives and methodologies 
that focus on enhancing or mitigating impaired cognitive performance in schizophrenia (e.g., 
Green et al., 2004; Marder & Fenton, 2004; Carter & Barch, 2007). In response to failed attempts 
at augmenting functional outcome via symptomatic improvement, the logic behind this initiative 
is that enriching a patient’s cognitive status should result in meaningful changes and 
enhancements in functional status and adjustment.  
Impaired Cognition as a Core Feature 
Importantly, the neurocognitive deficits observed in schizophrenia patients are intrinsic to 
the disorder and are not an epiphenomenon of the illness. There is substantial consensus in the 
literature that impairments in various cognitive domains are not reducible to secondary 
influences that reflect treatment with antipsychotic medications, recurrent hospitalization, social 
disadvantage, or years of chronic stress associated with receiving the diagnosis (Torrey, 2002; 
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Ma et al., 2007). They also persist following the amelioration of clinical symptoms and over the 
course of the illness (Elvevag & Goldberg, 2000; Heinrichs & Zakzanis, 1998; Hoff et al., 1999; 
Hughes et al., 2003; Martinez-Aran et al., 2002; Rund et al., 2004); exist in the pre-psychotic 
period and at the onset of illness (Brewer et al., 2005; Johnstone, Ebmeier, Miller, Owens, & 
Lawrie, 2005; Lencz et al., 2006; Lewandowski, Cohen, & Ongur, 2011; Mesholam-Gately, 
Giuliano, Goff, Faraone, & Seidman, 2009); occur in unaffected people with elevated risk 
(Cannon et al., 2000; Fusar-Poli et al., 2007; Sitskoorn, Aleman, Ebisch, Appels, & Kahn, 2004; 
Whalley, Harris, & Lawrie, 2007); are unrelated to the chronicity of the illness or its duration 
(Heaton et al., 2001; Hoff et al., 1999; Kurtz, Seltzer, Ferrand, & Wexler, 2005), and are more 
severe in schizophrenia, as compared with other psychotic illnesses (Altshuler et al., 2004).  
Intellectual/Cognitive Deterioration 
While cognitive impairment occurs across many ability areas, the universality, nature, 
onset and consequences of cognitive impairment in schizophrenia remain largely uncertain. It 
has been argued that the degree of intellectual deterioration subsequent to the onset of 
schizophrenia is central in the quest to identify more homogeneous groups within the 
schizophrenia patient population. This concept of intellectual decline, which was introduced by 
Kraepelin nearly a century ago, continues to figure prominently in the field of cognitive 
impairment in schizophrenia since intellectual status is believed to be an important correlate of 
most other cognitive and neuropsychological functions. In fact, it has been argued by some that 
almost all patients with schizophrenia undergo an intellectual function decrement (Keefe, Eesley, 
& Poe, 2005; Vaskinn et al., 2014). A
 
decline in general intellectual ability may occur in tandem 
with the first psychotic episode and then persist over the course of illness (Goldberg, Hyde, 
Kleinman, & Weinberger, 1993; Kurtz, 2005; Nelson et al., 1990).  
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Indirect evidence for the notion of intellectual decline comes from studies of 
monozygotic twin pairs discordant for schizophrenia in which each affected individual is 
compared to his or her co-twin, thus controlling for age, sex, and genome as well as 
environmental influences such as educational opportunity and socioeconomic status. In studies 
implementing this design, the twin with schizophrenia consistently performs worse on 
neuropsychological testing compared to his or her unaffected co-twin, regardless of how well the 
affected twin performed. For example, Goldberg
 
and colleagues (1995) showed that the 
unaffected twin scored an average of 10 points higher on IQ tests when compared to the affected 
twin.  Kremen and colleagues (2000) showed that chronic schizophrenia patients who were 
matched one-to-one on education with healthy control participants tended to have estimated 
premorbid abilities that are a full standard deviation above healthy control participants with 
similar cognitive performance. This concept of intellectual decline following illness onset has 
also been supported by longitudinal studies (Lubin, Gieseking, & Williams, 1962; Schwartzman 
& Douglas, 1962), as well as by studies of first-episode patients (Goldberg, Karson, Leleszi, & 
Weinberger, 1988). A recent meta-analysis found that although a substantial proportion of 
children and adolescents who go on to develop schizophrenia have normal range cognitive 
performance before the onset of illness, they then suffer a decline into below-average ranges that 
coincides with the onset of symptoms (Bouzikas & Androu, 2011). Population-based estimates 
of intellectual deterioration indicate rates as high as 98% for patients with schizophrenia, who 
show a measurable decrement in intellect from premorbid levels (Keefe et al., 2005). These data 
suggest that patients with schizophrenia, even those who perform within normal limits on 
neurocognitive tests, have in fact undergone a substantial decline in their level of intellectual or 
cognitive functioning.  
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Premorbid Intellectual/Cognitive Impairments  
However, intellectual decline after the onset of schizophrenia is not universally 
characteristic and may precede substantially the development of frank psychotic illness (Russell, 
Munro, Jones, Hemsley, & Murray, 1997). Russell and colleagues (1997) suggested that 
cognitive impairments are inherent to the disease process and that any ensuing intellectual 
impairment is due to a pre-existing deficit that predates the manifestation of psychotic symptoms 
and is thus not reducible to the pathological process of disease onset. Indeed, research has 
consistently linked schizophrenia to a variety of early neurodevelopmental abnormalities 
(Murray & Lewis, 1987; Weinberger, 1987; Seidman, 1990) and there is substantial evidence in 
the literature that as a group, individuals who later will be hospitalized for schizophrenia have 
impairments in various neurocognitive domains that precede the manifestation of psychotic 
symptoms (Bilder et al., 2000; Davidson et al., 1999; Kremen et al., 1998). For example, 
research has shown that deficits in perception, memory, language, and attention surface in early 
childhood long before the emergence of any psychotic symptoms (Cannon et al., 2000; 
Cornblatt, Obuchowski, Roberts, Pollack, & Erlenmeyer-Kimling, 1999; Erlenmeyer-Kimling et 
al., 2000). 
One measure that has received a great deal of attention as a potential indicator of early 
neurodevelopmental abnormality is general intellectual functioning or IQ. Several study designs 
allow for estimates of premorbid IQ, including retrospective studies of school-, recruit-, or clinic-
based testing, longitudinal birth or recruit cohort studies, and studies of population samples at 
genetic risk for schizophrenia (Agnew-Blais & Seidman, 2013; Khandaker, Barnett, White, & 
Jones, 2011; Woodberry, Giuliano, & Seidman, 2008). There are numerous retrospective 
estimates of low premorbid function (e.g., Torrey, Bowler, Taylor, & Gottesman, 1994) and 
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there are recent reports documenting low IQ in a substantial proportion of children and 
adolescents who later develop
 
schizophrenia (e.g., Cannon et al., 2000, 2002; Khandaker et al.,  
2011). In addition, large birth cohorts have found that individuals who later develop 
schizophrenia were often delayed in achieving neuromotor developmental milestones, have 
premorbid speech abnormalities, and have on average lower levels of educational achievement 
(Crow, Done, & Sacker, 1995; Poulton et al., 2000, Sorensen et al., 2010). Jones and colleagues 
(1994) using the 1946 birth cohort, obtained premorbid cognitive scores and found impairments 
in the educational test scores at ages 8, 11, and 15 of participants who later developed 
schizophrenia, and this was unrelated to the sex or social class of the subject. In a cohort of 
males conscripted into the Swedish army in 1969-1970, David and colleagues (1997) found a 
robust relationship between IQ and later risk of developing schizophrenia. In another Swedish 
conscript cohort, Gunnell and colleagues (2002) found that IQ score at the age of 18 years was 
correlated with risk of developing early-onset schizophrenia, and this relationship persisted after 
controlling for potential confounders such as prenatal adversity and obstetric complications. In 
the National Child Development Study, subjects were prospectively followed and it was found 
that those who developed schizophrenia had lower IQ scores at the age of 11 years compared 
with controls (Done, Crow, Johnstone, & Sacker, 1994). Similarly, in the Dunedin longitudinal 
birth cohort study, lower childhood IQ scores and receptive language impairments were found in 
children who subsequently developed schizophrenia (Cannon et al., 2002; Reichenberg et al., 
2010). In a case-control study of high school recruits for the Israeli military service, individuals 
with schizophrenia showed significant premorbid deficits on all intellectual measures and on 
measures of reading and reading comprehension (Reichenberg et al., 2002). The last quantitative 
review of the literature, which was published in 2008, suggested that years before the onset of 
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psychotic symptoms, individuals with schizophrenia, as a group, exhibit mean IQ scores roughly 
one-half of a standard deviation below that of healthy controls (Woodberry et al., 2008). These 
precursors of schizophrenia corroborate the hypothesis that psychosis arises from a cognitively 
compromised brain.  
Intellectual/Cognitive Preservation 
However, not all patients with schizophrenia show intellectual or cognitive impairments 
according to standard clinical norms. In fact, some studies have described high functioning 
schizophrenia patients with normal intellectual functioning and no or minimal cognitive deficits 
(e.g., Palmer et al., 1997; Kremen, Seidman, Faraone, Toomey, Tsuang, 2000; Rangel et al., 
2015). Meta-analytic findings aggregated from hundreds of studies and thousands of 
schizophrenia patients and healthy participants imply that 70-75% of the schizophrenia patient 
population performs below general population values on many standard neuropsychological tests 
(Heinrichs, 2005). Hence, a substantial minority, 20-25%, must overlap with healthy people on 
many standard cognitive tasks. Indeed, a number of studies have corroborated the implications of 
meta-analytic findings and identified groups of patients with schizophrenia displaying 
statistically average levels of neuropsychological functioning (Ammari, Heinrichs, & Miles, 
2010; Heinrichs et al., 2008; Leung, Bowie, & Harvey, 2008; Kremen et al., 2000; Palmer, 
Dawes, & Heaton, 2009; Palmer et al., 1997; Rund et al., 2006; Weickert et al., 2000; Wexler et 
al., 2009). In a seminal study, using a combination of expert ratings and normative criteria, 
Palmer and colleagues (1997) identified 27.5%
  
of their sample of schizophrenia patients as 
neuropsychologically normal on a variety of cognitive
 
measures, including general intellectual 
ability or IQ. This subgroup was statistically indistinguishable from the control group on a 
comprehensive test battery. Numerous later studies corroborated a 20-30% overall prevalence of 
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performance normality in schizophrenia across settings and samples (Allen, Goldstein, & 
Warnick, 2003; Kremen et al., 2000; Weikert et al., 2000). Furthermore, there are reports of even 
higher-functioning patient subgroups. Recent studies show that a much smaller, but potentially 
important, subgroup of patients demonstrates verbal ability at or above the 90
th
 percentile, based 
on Vocabulary scores from the Wechsler Adult Intelligence Scale (Heinrichs et al., 2008), an 
indicator of general intellectual ability.  Others have also identified patients who have IQs above 
the average range (Kremen, Seidman, Faraone, & Tsuang, 2001; McCabe, Maloney, Stain, 
Loughland, & Carr, 2012; Weikert et al., 2000; Wilk et al., 2005). These cognitively exceptional 
schizophrenia patients are indistinguishable from demographically matched control participants 
on a wide range of neuropsychological measures.  
It has been argued that the occurrence of intellectual and cognitive normality in 
schizophrenia may still reflect a decline from superior ability preceding the onset of the illness 
(e.g., Wilk et al., 2005). Therefore patients who currently perform in the average range on 
cognitive tasks, including IQ measures, would have theoretically scored in the above-average 
range had they been assessed prior to illness onset.  Nonetheless, they share the cognitively 
impairing disease process with the rest of the patient population and thus undergo cognitive 
deterioration into the average range following the onset of their illness. Consequently, an 
additional criterion for normality used by some researchers requires equivalence between current 
and estimated premorbid levels-of-performance. Oral reading tasks are often used to provide 
estimates of premorbid cognitive capabilities insofar as they are believed to reflect preserved 
abilities routinely acquired before the onset of schizophrenia (Allen et al., 2003; Harvey et al., 
2000; Lezak, Howieson, Loring, Hannay, & Fischer, 2004; Warnock, Allen, & Goldstein, 2000). 
Many studies of premorbid abilities in patients with normal cognitive performance did not find 
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any evidence of a discrepancy between current and premorbid estimates of cognitive functioning 
based on reading tasks (McCabe et al., 2012; Heinrichs et al., 2008; Weikert et al., 2000). 
Therefore, schizophrenia can occur in the relative absence of cognitive impairment in a minority 
of patients, and there is no evidence that these patients have undergone a decline in their 
intellectual ability. Furthermore, it seems doubtful that the 20%-30% of cognitively normal 
schizophrenia patients in typical outpatient samples would all have had superior cognitive 
abilities had they not become ill, as that is an inexplicably large proportion of people to have 
cognitive capabilities one to two standard deviations above the population mean.  
Patterns of Intellectual Ability in Schizophrenia 
In light of the heterogeneity in intellectual performance patterns observed in 
schizophrenia and given the inconsistencies in the literature regarding issues of intellectual 
decline, premorbid impairments, and preserved abilities, a typology comprising preserved, 
deteriorated, and premorbidly impaired intellectual ability patterns has been proposed and 
received partial support (Badcock, Dragović, Waters, & Jablensky, 2005; Leeson et al., 2011). 
Research has suggested that patients with relatively preserved intellect function at higher levels 
in the community and maintain that level of functioning for longer periods of time when 
compared to more typical patients (Ammari et al., 2010; McKibbin, Brekke, Sires, Jeste, & 
Patterson, 2004; Wells et al., 2015). They also tend to have fewer symptoms and receive less 
anticholinergic medication than their neuropsychologically impaired counterparts (Palmer et al., 
1997; Seidman, Cassens, Kremen, & Pepple, 1992; Wells et al., 2015).  
Murray and associates (Murray & Lewis, 1987; Murray, Jones, O’Callaghan, Takei, & 
Sham, 1992) proposed an etiological theory which could explain the existence of intellectually 
preserved and impaired subgroups. They suggested that schizophrenia has a different 
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neurodevelopmental cause in impaired patients, which has its roots in genetic deficiencies and 
early risk factors such as birth complications. These patients are distinguished by premorbid 
motor and behavioural problems, cognitive deficits, inferior social adjustment, early illness 
onset, and more severe negative symptoms. The intellectually preserved patients also have a 
susceptibility to decompensate into psychosis, but there is less evidence of a neurodevelopmental 
disease and they are less likely to exhibit premorbid problems or cognitive impairments. The 
existence of such patients could have significant implications for understanding the 
neuropathology of schizophrenia in that they suggest that psychotic symptoms and 
neurocognitive function are relatively independent dimensions of the disorder. 
Structural abnormalities in Schizophrenia 
Innovations in imaging technology have stimulated the enormous upsurge of 
schizophrenia research over the last three decades. This research is driven by inferences that the 
disease develops, at least partly, as a result of deficiencies in aspects of brain structure and 
function. Indeed, complex and widespread patterns of brain abnormalities appear to be a 
hallmark of schizophrenia and are believed to be shaped by a combination of 
neurodevelopmental and neurodegenerative abnormalities (Keshavan, Tandon, Boutros, & 
Nasrallah, 2008). In this view, schizophrenia is a neurobiologic disorder affecting the 
development and formation of brain structures, which consequently disrupts neuropsychological 
functioning (Keshavan et al., 2008). While impaired cognitive performance is believed to signal 
the neuropathological disease process rather than the unstable and sometimes volatile nature of 
the clinical symptoms, the neuropathological substrates of cognitive impairment in schizophrenia 
are not well established and relatively few consistent findings have emerged to map 
neurobiology directly onto neurocognitive performance. Nevertheless, intricate and 
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heterogeneous patterns of structural aberrations may underlie the heterogeneity observed in 
neurocognitive functioning. Analysis of brain morphology in schizophrenia patients with 
differing intellectual profiles can help explicate the relationships between cognitive functioning 
and disease-related alterations in brain anatomy.  
Indeed, recent work has suggested that differences in the level of neurocognitive 
impairment are related to differential patterns of structural change in the cerebral cortex. 
Specifically, it has been argued that cortical thickness is particularly relevant in terms of illness 
etiology. In fact, one of the principal pathological findings in the brains of those affected with 
schizophrenia involves abnormal cortical thinning (Cannon et al., 2015). Reduced cortical 
thickness has also been demonstrated in the unaffected siblings of patients with the disorder 
(Goldman et al., 2009; Goghari, Rehm, Carter, & MacDonald, 2007; Gogtay et al., 2007), 
suggesting a possible relationship of these cortical changes to the genetic liability for developing 
the illness. Indeed, schizophrenia’s strongest genetic association involves variation in the major 
histocompatibility complex (MHC) locus, which mediates synapse elimination during postnatal 
development in mice (Sekar et al., 2016). Sekar and colleagues (2016) argued that excessive or 
inappropriate synaptic pruning during adolescence and early adulthood contribute to the 
development of the illness and may help explain the observed cortical thinning. Overall, 
widespread reductions in cortical thickness across various brain regions have been reported in 
schizophrenia patients with cognitive impairments, particularly in frontal and temporal regions 
(Goldman et al., 2009; Kuperberg et al., 2003; Nesvag et al., 2008; Schultz et al., 2010). 
Reasonably consistent relationships are also reported between verbal memory impairment and 
cortical thinning in the medial temporal lobe (Antonova, Sharma, Morris, & Kumari, 2004; Gur, 
Keshavan, & Lawrie, 2007; Lawrie, Johnstone, & Weinberger, 2004). A number of meta-
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analyses have synthesized evidence on several aspects of fronto-temporal anatomy in 
schizophrenia. Bora and colleagues (2011) corroborated findings of reduced cortical thickness in 
prefrontal, temporal, and parietal cortices (Bora et al., 2011).  
Only a handful of studies have investigated differences in the brain structure of cognitive 
subgroups in schizophrenia. An investigation by Wexler and colleagues (2009) used structural 
MRI to compare cognitively “near normal” and cognitively impaired patients on detailed 
measures of regional brain volumes of gray and white matter across the cerebrum. Patients were
 
assigned to the neuropsychologically near normal subgroup
 
if they scored within 0.5 standard 
deviation of comparison
 
participants on four tests of attention and verbal and nonverbal
 
working 
memory and to the neuropsychologically impaired group if they scored at least 1.0 standard 
deviation below that
 
of comparison participants. sMRI scanning revealed markedly smaller white 
matter volumes in sensorimotor and parietal regions and larger volumes of the lateral ventricles 
in the impaired patients when compared to the cognitively intact patients, who were 
indistinguishable from healthy controls. However, both patient groups had markedly less gray 
matter volume throughout the cerebrum and markedly larger third ventricles than healthy 
comparison participants. Cobia and colleagues (2011) found that ‘neuropsychologically near-
normal’ schizophrenia patients, defined using a series of clustering algorithms, exhibited reduced 
cortical thinning when compared to healthy controls. They concluded that a compelling 
association exists between cognitive impairment and cortical thinning in schizophrenia, where 
patients with normal or near-normal cognitive abilities also exhibit normal or near-normal 
cortical thickness patterns.  
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Study Aim 1 
In light of these considerations, the first aim of the present investigation was to identify 
and estimate the prevalence of intellectual performance patterns corresponding to preserved, 
deteriorated, and premorbidly impaired ability in a large sample of schizophrenia patients 
through application of algorithms derived from standard cognitive test data. Subtypes based on 
intellectual ability may organize and reduce the heterogeneity of schizophrenia, aid in the 
prediction of functional outcome, and lend themselves to biological validation. A detailed 
characterization of these intellectual subtypes may be important in targeting appropriate 
treatment approaches, management of symptoms and deficits, and establishing or determining 
services for patients with schizophrenia. Given that the course and progression of schizophrenia 
is highly variable, the ability to predict long-term functional outcome would be extremely helpful 
for treatment and rehabilitation planning.  
For the purpose of this study, premorbid intellectual ability was estimated using a word 
reading measure. Oral single-word reading tests are widely viewed as an index of premorbid 
ability insofar as they are believed to reflect preserved abilities routinely acquired before the 
onset of schizophrenia (Allen et al., 2003; Harvey et al., 2000; Kremen, Seidman, Faraone, 
Pepple, Lyons, & Tsuang, 1996; Lezak et al., 2004; Warnock et al., 2000) and seem to resist the 
influence of various types of acquired diffuse and multi-focal neurological disease (see Franzen, 
Burgess, & Smith-Seemiller, 1997 for a review). It is also believed to be a skill resistant to a 
variety of psychiatric disorders including schizophrenia (Bright, Jaldow & Kopelman, 2002; 
Green et al., 2008; Harvey et al., 2006; Heinrichs & Zakzanis, 1998; Miller, Marks & Halperin, 
2005; Rolstad et al., 2008). Therefore, a reading score is a feasible predictor of whether a 
patient’s current intellectual or cognitive ability is congruent with earlier expectations. For the 
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purposes of this study, global cognitive ability will be considered in terms of verbal and 
nonverbal ability. Verbal ability, indexed by vocabulary test scores, and nonverbal ability, 
indexed by reasoning with visual shapes and patterns, are robust indicators of general 
intelligence. IQ-based estimates of global cognitive ability may deviate from levels of 
performance observed on reading tests. For example, Badcock and colleagues (2005) reported 
subgroups of schizophrenia patients with normal range IQ and reading scores, below normal 
reading and IQ scores, but also a subgroup with below average IQ scores and normal range 
reading. These differences provided the basis for the proposed intellectual subtypes.  
Study Aim 2 
The second aim of this study was to evaluate the cognitive validity of these intellectual 
subtypes by comparing performance on independent adjunct measures of cognitive ability and 
relative to the performance of healthy research participants. Although some studies found that 
schizophrenia patients with average range intellectual ability are truly free of other cognitive 
deficits (Ammari et al., 2010), others found that patients may perform in the average range on a 
composite score like IQ, but still demonstrate abnormalities in executive, attention-related, 
memory, and processing speed abilities (Allen et al., 2003; Gray, McMahon, & Gold, 2013; 
Holthausen et al., 2002; Joyce et al., 2002; Kremen et al., 2000; Weickert et al., 2000) when 
compared directly with a healthy control group. These cognitive domains are highly vulnerable 
to many neurological events and disease processes. For example, Weickert and colleagues (2000) 
compared standard assessments of premorbid and current IQ and reported that patients with 
schizophrenia displaying preserved intellectual ability exhibited a cognitive profile that was 
similar to that of healthy controls except on specific tasks of attention and executive functioning 
(Wisconsin Card Sorting Test and Continuous Performance Test). They concluded that executive 
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impairment comprises a “necessary type of cognitive impairment in schizophrenia” (Weickert et 
al., 2000). Similarly, Kremen and colleagues (2001) reported that patients with preserved IQ 
exhibit a broad spectrum of compromised neuropsychological performance when compared with 
IQ-matched controls. Gray and colleagues (2013) argued that general intellectual ability or IQ 
does not explain the generalized deficit observed across multiple cognitive domains in 
schizophrenia. They found that patients performed on average one full standard deviation worse 
on a neuropsychological battery than what would be expected based solely on their current and 
estimated premorbid IQ scores.  
In exploring the question of preserved cognitive ability in schizophrenia, evidence from 
specialized “cognitive neuropsychiatry” tasks will also be considered. These more specialized 
and less frequently utilized tasks evolved from research on cognitive biases and social reasoning 
in patients with psychotic disorders, and they include probabilistic reasoning, source attribution, 
and theory-of-mind paradigms. Research has suggested that more severe levels of 
psychopathology, particularly symptoms such as delusions and thought disorder, are associated 
with deficient performance on tests tapping these abilities (Brune, 2005; Bora, Yucel, & Pantelis, 
2009; Corcoran, Mercer, & Frith, 1995; Dudley, Taylor, Wickham, & Hutton, 2015; Frith & 
Corcoran, 1996; Garety, Hemsley, & Wessely, 1991; Garety et al., 2005; Kinderman & Bentall, 
1996). These specially constructed measures have not, thus far, been applied to the study of 
intellectual subtypes in schizophrenia. The notion of bias or style in cognitive processing refers 
to both formal and social reasoning partiality and includes a propensity to make decisions based 
on inadequate data, a resistance to disconfirmatory information, and ‘self-serving’ attributions in 
social situations. For example, the most often cited effect originates from the observation that 
schizophrenia patients with persecutory delusions are inclined to ‘jump to conclusions’ and make 
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impulsive and premature decisions exclusive of sufficient information on probabilistic reasoning 
tasks (Dudley et al., 2015; Lincoln, Ziegler, Mehl, & Rief, 2010; Garety et al., 1991; Garety et 
al., 2005; So, Garety, Peters, & Kapur, 2010). Delusional patients also tend to rigidly hold their 
beliefs and refuse to consider any disconfirmatory evidence (Woodward, Moritz, Cuttler, & 
Whitman, 2006). In addition, these patients have trouble envisioning others’ intentions or 
drawing plausible conclusions about the motives of others (Corcoran et al., 1995; Frith & 
Corcoran, 1996; Brune, 2005; Harrington, Langdon, Siegert, & McClure, 2005; Harrington, 
Siegert, & McClure, 2005), an ability widely known as Theory of Mind which has been defined 
as the “capacity to represent one’s own and other persons’ mental states” (Brune, 2005, p 21). 
Schizophrenia patients also demonstrate a persistent “externalizing” attribution style in that they 
often assign the causes of undesirable or negative personal occurrences to other people or to the 
external world (Kinderman & Bentall, 1996; Kaney & Bentall, 1989).  
Although there is some evidence that the ‘jumping to conclusions’ tendency is 
independent of general intellectual ability (Langdon, Ward, & Coltheart, 2010; van Hooren et al., 
2008), very little is known about whether there are consistent patterns of association between 
other cognitive biases and general intellectual ability. Thus, the question of whether the proposed 
intellectual subtypes demonstrate the same degree of cognitive biases despite their distinct 
intellectual profiles will be explored. Roncone and colleagues (2002) asserted that intellectual 
ability is an insufficient explanation for the observed theory-of-mind deficits in schizophrenia. 
On the other hand, other studies found that performance on tests requiring schizophrenia patients 
to discern the intentions of others was associated with IQ (Brune, 2003), as well as with tests of 
memory (Greig, Bryson, & Bell, 2004) and executive function (Greig et al., 2004; Langdon, 
Coltheart, Ward, & Catts, 2002). Nevertheless, the majority of evidence implicates level of 
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psychopathology as a better predictor than intellect or cognitive ability of performance on tests 
tapping cognitive bias or style.  
Study Aim 3 
The third aim was to assess the severity of clinical symptoms across the intellectual 
subtypes. Numerous findings have shown that relations between symptom dimensions or severity 
and neurocognitive performance are feeble or often nonexistent across many clinical samples 
(Berenbaum, Kerns, Vernon, & Gomez, 2008; Dibben, Rice, Laws, & McKenna, 2009; 
Dominguez, Viechtbauer, Simons, Van Os & Krabbendam, 2009; Heinrichs et al., 2008; Waters, 
Badcock, Dragovic, & Jablensky, 2009; Wexler et al., 2009).  For example, comparisons of 
cognitively impaired and normal or near-normal schizophrenia patients have repeatedly shown 
that cognitive performance, including IQ, and positive symptoms such as delusions and 
hallucinations are independent (Ammari et al., 2010; Cobia et al., 2011; Heinrichs et al., 2008; 
Holthausen et al., 2002; Palmer et al., 1997; Wexler et al., 2009).  On the other hand, there have 
been reports of moderate correlations between negative symptoms and standard neurocognitive 
tasks, although the common variance is seldom more than 15% (Ammari et al., 2010; Cobia et 
al., 2011; de Gracia Dominguez, Viechtbauer, Simons, van Os, & Krabbendam, 2009; 
Greenwood, Sigmundsson, Morris, & Wykes, 2000; Vaz & Heinrichs, 2006; Palmer et al., 
1997), but others failed to find a relationship (Holthausen et al., 2002; Heinrichs et al., 2008; 
Palmer et al., 1997; Wexler et al., 2009). A similar discrepancy occurs with regards to 
disorganization symptoms in schizophrenia (Holthausen et al., 2002; Cobia et al., 2011). 
Dominguez and colleagues (2009) systematically reviewed 58 studies published between 1986 
and 2007 and synthesized the reported correlations between symptoms and cognitive 
performance in schizophrenia. They found that negative and disorganized symptom dimensions 
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were significantly but modestly associated with cognitive deficits, whereas positive and 
depressive dimensions of psychopathology were not associated with neurocognitive measures. 
Another independently conducted meta-analysis largely corroborated these results (Ventura, 
Thames, Wood, Guzik, & Hellemann, 2010).  
Study Aim 4 
Finally, this study aims to examine the neuroanatomical characteristics of these 
potentially important subgroups using cortical thickness mapping. Although the brain imaging 
literature on schizophrenia patient-control differences in regional anatomy and physiology is 
vast, relatively few consistent findings have emerged to map neurobiology directly onto 
cognitive performance (Ragland, Yoon, Minzenberg, & Carter, 2007). Further, there has been no 
detailed examination of cortical thinning patterns to compare patients with preserved, 
deteriorated, and premorbidly impaired intellect. The only published study of brain structure 
anomalies in intellectually-defined subgroups of schizophrenia patients found that those with 
below-average estimated premorbid ability exhibit evidence of early cerebral hypoplasia, 
whereas intellectually preserved and deteriorated patients show evidence of brain tissue loss 
consistent with progression or later cerebral dysmaturation (Woodward & Heckers, 2015). 
However, this study specifically examined intracranial and total brain volume and did not 
include an analysis of cortical thinning patterns. All other studies examining the brain structure 
of schizophrenia patients grouped according to cognitive variables have been limited to 
comparing cognitively normal and impaired patients, without consideration of intellectual status 
or pattern. 
Biological validation of the proposed intellectual subtypes requires the demonstration that 
differences in intellect between the patient groups correspond to neurobiological differences 
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indicating that these behavioural distinctions map onto neural substrates. Overall, studying the 
characteristics of the proposed intellectual subtypes may inform our understanding of specific 
heterogeneous pathophysiological processes underlying the illness. Further, results should 
provide an indication of whether these subtypes hold potential as organizing principles for 
research on the heterogeneity of schizophrenia. It is possible that these patient subgroups differ 
in their intellectual abilities because they have fundamentally distinct illnesses in terms of their 
underlying pathophysiology and thus also in their effects on the structure and function of the 
brain. Alternatively, the underlying brain abnormalities may differ on a quantitative versus 
qualitative scale, which would support a dimensional view of the illness. For example, the 
intellectually preserved subtype may constitute an aggregate of patients with less severe 
cognitive impairments and potentially less marked neurobiological abnormalities than those 
observed in patients with deteriorated and premorbidly impaired intellect.   
Model and Hypotheses 
The working model is that each of the proposed intellectual patterns represents a distinct 
illness variant within the schizophrenia patient population, each with a corresponding expression 
of psychopathology, cognitive profile, and neurobiological substrate. The most compelling 
validation of the proposed intellectual subtypes necessitates evidence of shared as well as non-
shared characteristics. While there may be substantial individual differences in the expression of 
particular symptoms, the three intellectual patient groups have a common diagnosis and 
consequently a shared clinical syndrome of psychopathology. A great deal of evidence suggests 
that psychopathology, especially psychotic symptoms, and impaired intellectual or cognitive 
performance are separable processes in schizophrenia. If the psychopathological and 
neurocognitive manifestations of schizophrenia originate from autonomous disease processes, 
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then all patient groups should exhibit comparable symptom severity levels regardless of their 
discrepant intellectual profiles.  Such weak or absent associations between intellectual or 
cognitive functioning and psychopathology make it difficult to argue that a single disease 
process underlies both psychosis and impaired cognition in schizophrenia. Instead, the lack of 
consistent relationship implies a dual-process disease model wherein cognitive deficits may 
occur in the absence of psychotic symptoms and vice versa. In light of the evidence, it is 
hypothesized that the intellectual subgroups will be indistinguishable from each other on 
symptom severity measures.  
Accordingly, key neural systems mediating this psychopathology are also shared across 
the three subtypes. These shared illness characteristics presumably reflect the psychosis-
producing process. To that extent, patterns of intellectual profiles may be of little relevance to 
the neuropathological and pathophysiological mechanisms underlying the psychiatric symptoms 
in schizophrenia. However, the three patient groups do not share the same level of intellectual 
and possibly cognitive performance. It follows then that these groups will also be 
neurobiologically distinct, signifying the relative preservation and pathology of underlying 
neuromechanisms.  For example, if intellectually preserved patients have the psychosis-
producing process that defines the illness, but little of the defective cognition observed in more 
typical patients, this behavioural difference should demonstrate biological validity by mapping 
onto cerebral differences.  In other words, patients with preserved intellectual profiles may also 
demonstrate ‘preserved’ brain structure commensurate with their intellectual and cognitive 
status. Two patterns of cortical thinning are hypothesized; one pattern that is shared by all patient 
groups and that distinguishes them from healthy comparison subjects and one that distinguishes 
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the patient groups from each other and thereby associates with intellectual or cognitive 
performance.  
Based on previous studies, it is hypothesized that patients with both premorbid and 
morbid intellectual deficits would exhibit more generalized or widespread deficits in cognitive 
performance, including memory, visuospatial perception, attention, executive function, language, 
and psychomotor deficits. Correspondingly, it is hypothesized that these findings would 
associate with widespread cortex dysfunction in the premorbidly impaired group. On the other 
hand, it is hypothesized that patients with evidence of intellectual decline following the onset of 
schizophrenia will display impairments in executive functioning, attentional abilities, and 
memory. This would implicate frontotemporal dysfunction. Finally, it is hypothesized that 
patients meeting the criteria of intellectual preservation will present with a milder and more 
limited range of cognitive impairments and demonstrate a less marked neuropathological pattern, 
with smaller regions of thinning consequent to a cognitively milder form of the disease.  
2. Method 
2.1 Participants 
Patients were recruited from both inpatient and outpatient settings in Hamilton, Ontario, 
Canada that required active program attendance and comprised vocational and/or social 
rehabilitation and training activities. Settings included the Hamilton Program for Schizophrenia 
(HPS), the Community Schizophrenia Service (CSS, St. Joseph's Healthcare Hamilton), the 
Cleghorn Early Intervention in Psychosis Clinic (St. Joseph's Healthcare Hamilton), the 
Schizophrenia and Community Integration Service (St. Joseph's Healthcare Hamilton), 
Schizophrenia Services of Ontario, Hamilton Chapter, Path Employment Services, and the 
Wellington Psychiatric Outreach Program. 
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Male and female participants who met the following criteria were included: (1) diagnosis 
of schizophrenia or schizoaffective disorder by the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV; American Psychiatric Association, 2000) criteria confirmed 
by the Structured Clinical Interview for DSM-IV Axis I Disorders-Patient version (SCID; First, 
Spitzer, Miriam, & Williams, 2002); (2) age 18-65 years; (3) no history of serious neurological 
or endocrine disorder, including head trauma, epilepsy, Cushing’s disease or thyroid disorder; (4) 
no concurrent diagnosis of substance use disorder; (5) no history of developmental or learning 
disability; (6) ability to understand spoken English sufficiently to comprehend testing 
procedures; (7) willingness and ability to sign informed consent; (8) eligibility for MRI scanning 
procedure and; (9) normal or corrected vision. A total of 71 patients, including 44 males and 27 
females, met inclusion criteria. Patients ranged from 20 to 63 years of age, with a mean of 41.27 
(SD = 10.63).  
Healthy control participants (n = 66) were recruited through local postings and 
advertisements for paid research participation in community newspapers and online classified 
advertisements in Hamilton, Ontario and Toronto, Ontario. Potential control participants were 
screened for medical and psychiatric illness and history of substance use disorders. This 
recruitment effort yielded 38 males and 28 females, ranging from 19 to 65 years of age, with a 
mean age of 39.61 (SD = 12.12). All participants provided written informed consent and were 
paid for their time. The project was approved by the institutional review board at each research 
site and by the research ethics board at St. Joseph’s Healthcare Hamilton and York University.  
2.2 Psychopathology Measures 
 Patients’ medical charts were reviewed to determine presence, type (e.g., haloperidol, 
clozapine, olanzapine) and dose of anti-psychotic medications. The presence and type of other 
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psychotropic medications were also recorded. Current symptoms were assessed with the Positive 
and Negative Syndrome Scale (PANSS; Opler, Kay, Lindenmayer, & Fiszbein, 1999). The 
PANSS provides severity ratings of positive, negative, and general psychiatric symptoms 
common to patients with schizophrenia based on a semi-structured interview format. More 
specifically, the positive scale assesses symptoms such as delusions, hallucinations, conceptual 
disorganization, grandiosity, and persecutory ideation; the negative scale addresses blunted 
affect, emotional and social withdrawal, poor rapport, and rigidity of attitudes and beliefs. The 
general scale assesses symptoms such as somatic preoccupation, anxiety and tension, feelings of 
guilt, depression, odd mannerisms, bizarre thought content, disorientation and insight, and 
disturbance of volition. Each of the 30 items which constitute these three broad scales is scored 
on a 7-point scale, with detailed rating anchors ranging from the absence of symptoms to 
extreme psychopathology. The PANSS has shown high internal reliability and homogeneity 
among its items, with coefficients ranging from .73 to .83 (Kay, Opler, & Fiszbein, 2000). 
Furthermore, test-retest reliability indices for unremitted patients ranged from .77 to .89 on the 
core scales. The positive and negative scales are inversely correlated with each other once their 
common association with general psychopathology is extracted, supporting their mutually 
exclusive dimensions. Inter-rater reliability has been shown to vary between .83 and .87.  
2.3 Cognitive Performance Measures 
Neuropsychological tests measuring several aspects of cognitive brain function were 
administered to all patients and healthy participants. English language versions of all measures 
were used. These measures included the Vocabulary and Matrix Reasoning subtests of the 
Wechsler Abbreviated Scale of Intelligence (WASI; Wechsler, 1999). The Vocabulary measure 
is an index of verbal ability, and requires participants to provide word definitions. Matrix 
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Reasoning provides an index of non-verbal ability, and involves logical reasoning with visual 
patterns. These two sets of abilities provided an estimate of current IQ.  IQ provides a single, 
global metric that reflects the overall intellectual ability of an individual and is believed to reflect 
enduring cognitive traits. Notably, the two-subtest WASI does not include measures of working 
memory or processing speed. Consequently, WASI-estimated IQ scores are likely to be higher 
than actual Wechsler Adult Intelligence Scale-III (WAIS-III; Wechsler, 1997) and WAIS-IV 
(Wechsler, 2008) scores. 
The Reading subtest of the Wide Range Achievement Test – Fourth Edition (WRAT-4; 
Wilkinson & Robertson, 2006), which requires individuals to read aloud a list of words with 
increasingly more difficult pronunciations, was used to estimate premorbid intellectual ability. 
As previously stated, the Reading subtest of the WRAT4 is thought to reflect preserved abilities, 
since it is a test of decoding skills normally acquired before the onset of disease and appear to be 
less vulnerable than other abilities to several neurological and psychiatric disease processes 
including schizophrenia (Allen et al., 2003; Goldberg et al., 1995; Harvey et al., 2000; Kremen et 
al., 1996; Warnock et al., 2000). 
The MATRICS (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) Consensus Cognitive Battery (MCCB) was also administered (Nuechterlein et 
al., 2008). The standardized battery includes individual measures of processing speed (Category 
fluency, Symbol coding, Trail making A), attention/vigilance (Continuous Performance Test, 
Identical Pairs [CPT-IP]), working memory (Letter-Number Sequencing [WAIS-III], Spatial 
Span [Wechsler Memory Scale III]), verbal learning and memory (Hopkins Verbal Learning 
Test-Revised), visual learning and memory (Brief Visuospatial Memory Test-Revised), 
reasoning and problem solving (Mazes [Neuropsychological Assessment Battery]), and social 
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cognition (Mayer-Salovey-Caruso Emotional Intelligence Test [MSCEIT]). It also yields a 
composite index of overall performance. The battery is regarded by experts as pertinent to 
schizophrenia and schizophrenia-related disorders and was formulated following a broad-based 
consensus process including the academic community and the National Institutes of Health 
(NIH; Nuechterlein et al., 2004). It is the only measure of cognitive performance that was 
developed under NIMH contract with contribution from the U.S. Food and Drug Administration. 
Consequently, it is recommended for all clinical trials of cognition-enhancing medications for 
schizophrenia. The selection of tests was based on considerations of efficiency, validity and 
reliability, and the nature and number of separable ability factors underpinning cognitive 
performance in schizophrenia patients (Nuechterlein et al., 2004).  
In addition, four specialized cognitive neuropsychiatry tests of biased reasoning, 
cognitive processing style, and social cognition were administered. Biased probabilistic 
reasoning was measured with a recent modification (Speechley, Whitman, & Woodward, 2010) 
of the standard ‘jumping to conclusions’ task initially developed by Garety and colleagues 
(Garety et al., 1991). In this probabilistic reasoning task (also known as the “Beads Task”), 
subjects judged which of two jars a sequence of coloured beads had been taken from. Difficulty 
was manipulated by varying the ratios of coloured beads in the jars. After each bead was drawn, 
participants were asked if they would like to see more beads (i.e., if they would like more 
information) or if they could say, with certainty, from which of the jars the beads were being 
drawn. The key variable was the number of beads requested by the participant before making a 
decision.  
Two aspects of social cognition with established sensitivity to positive symptoms were 
also assessed: an externalizing attribution tendency and theory-of-mind. As previously stated, 
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patients with delusions have difficulty imagining the intentions of others (Corcoran et al., 1995; 
Frith & Corcoran, 1996; Brüne, 2005) and tend to blame others for negative events (Kinderman 
& Bentall, 1996). Externalizing attributions for negative events were measured with the Internal, 
Personal and Situational Attributions Questionnaire (IPSAQ), which was developed and 
validated by Kinderman and Bentall (1997) as well as by independent investigators (Donohoe et 
al., 2008; Mizrahi, Addington, Remington, & Kapur, 2008). The IPSAQ is composed of 32 
hypothetical social situations, half depicting situations with  positive outcomes and half depicting 
situations with negative outcomes. The respondent is asked to provide the one most likely causal 
explanation for each situation. The respondent is then asked to classify this cause as being 
something due to themselves (internal attribution), something due to another person or persons 
(external-personal), or something due to the circumstances or chance (external-situational). 
Theory-of-mind or reasoning about the mental states of other people was measured with 
the Faux Pas Recognition Test (Stone, Baron-Cohen, & Knight, 1998; Gregory et al., 2002) and 
the Reading the Mind in the Eyes test (Baron-Cohen, Wheelwright, Hill, Raste, & Plumb, 2001). 
The Faux Pas is a verbal task that requires that the participant recognize whether a character in a 
short story may have inadvertently hurt the feelings of someone else, whereas the Reading the 
Mind in the Eyes test is a visual task that requires making deductions about the emotions from 
images of different people’s eyes. All measures were administered and scored by trained clinical 
research assistants using standard administration instructions and guidelines provided in the 
manuals. 
2.4 Classification of Participants 
As previously mentioned, current intellectual functioning was estimated based on the 
Vocabulary and Matrix Reasoning subtests of the WASI, from which reliable estimates of Full 
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Scale IQ (FSIQ) can be derived (Wechsler, 1999). An estimate of prior intellectual function was 
obtained from the Reading subtest of the the Wide Range Achievement Test – 4th Edition 
(WRAT-4, Wilkinson & Robertson, 2006), which measures recognition and pronunciation of 
printed words. Based on the categorization method previously described by Weickert and 
colleagues (2000), patients were classified into three distinct intellectual level subgroups as 
follows: (1) those displaying a decline in IQ (≥ 10 points) as evidenced by the difference 
between current IQ (based on a 2-subtest version of the WASI) and premorbid IQ (based on 
WRAT-4 Reading standard score), who will be referred to as intellectually deteriorated (n = 14); 
(2) those displaying both premorbid and current IQ estimates below 90 and no evidence of IQ 
decline greater than 10 points, who will be referred to as premorbidly impaired (n=14), which is 
consistent with the work of David and colleagues (1997) and with conventional usage (less than 
the 16th percentile, Wechsler, 1997); and (3) those whose premorbid and current IQ estimates 
were above 90 and who demonstrated less than a 10-point difference between their premorbid IQ 
based on WRAT-4 Reading and their current IQ based on the WASI, who will be referred to as 
intellectually preserved (n=29). Existence of a 10-point IQ decline took precedence to either of 
the cut-off strategies described. The control group met criteria for the preserved pattern (n=36). 
This classification method has been consistently used by investigators examining preserved, 
deteriorated, and premorbidly impaired intellect in patients with schizophrenia (e.g., Ammari et 
al., 2014; Badcock et al., 2005; Wells et al., 2015).  
2.5 MRI Acquisition Parameters  
All participants underwent MRI scanning at the Brain Imaging Research Centre, Brain-Body 
Institute, St. Joseph’s Healthcare Hamilton. Scans were acquired using a 3.0 Tesla whole body 
short bore General Electric MRI scanner with an 8-channel parallel receiver head coil. High-
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resolution images were obtained with a T1-weighted three-dimensional (3D) fast spoiled 
gradient (SPGR) echo sequence with inversion recovery preparation. The anatomical image had 
152 slices (2 mm thick with 1 mm overlap) with the following imaging parameters: time to 
repetition (TR)/ echo time (TE) = 7.5/2.1 ms, TI = 450 ms, field of view (FOV) = 24 cm, 
acquisition matrix size = 512 x 512, flip angle = 12ᵒ, receiver bandwidth (rBW) = +/-62.5 kHz, 
and number of excitations (NEX) = 1.  
2.6 MRI Processing 
The structural T1-weighted images collected for each participant were pre-processed in order 
to segment the brain and to align cortical structures across the subjects using the FreeSurfer 
toolkit version 5.1.0 (http://surfer.nmr.mgh.harvard.edu; Dale, Fischl, & Sereno, 1999; Fischl, 
Sereno, & Dale, 1999). Cortical thickness was defined as the distance between pial surface to the 
gray/white matter border at each vertex. Each MR image was intensity corrected, skull stripped 
and then automatically segmented into gray and white matter volumes.  These segmentations 
were then manually inspected and edited for accuracy according to established guidelines 
(Segonne, Pacheco, & Fischl, 2007). This method uses both intensity and continuity information 
from the entire three dimensional MR volume in segmentation and deformation procedures to 
produce representations of cortical thickness, calculated as the closest distance from the 
gray/white boundary to the gray/CSF boundary at each vertex on the tessellated surface (Fischl 
& Dale, 2000). A 2-dimensional smoothing kernel was applied along the cortical surface with a 
20mm full-width/half-maximum window. Spherical maps for each subject were morphed into a 
common spherical atlas using a nonlinear surface-registration procedure that allows for high-
registration, surface-based averaging, and comparison of cortical measurements across subjects. 
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2.7 Statistical Analyses 
The Statistical Package for the Social Sciences (SPSS), Version 23.0, was used for data 
analysis. Independent sample t-tests and Chi-square statistics were used to examine differences 
in demographic variables. Other statistical tests for the analysis of categorical data were 
considered, but the Chi-square statistic was deemed to be the most suitable. Group comparisons 
on symptom and neuropsychological measures were conducted using analysis of variance 
(ANOVA) models and planned comparisons, followed by Bonferroni post hoc comparisons. 
Predictions that specify directionality used 1-tailed tests and all others used 2-tailed tests. The 
same statistical analysis applied to test the prediction regarding the cognitive neuropsychiatry 
measures.  
Scans were analyzed and processed using FreeSurfer release 5.1.0. Surfaced-based 
analysis of cortical thickness involved generation of statistical surface maps utilizing a general 
linear model to display differences in thickness between groups at every vertex. Key 
demographic variables were not controlled, as these variables did not statistically differ between 
groups. False Discovery Rate (FDR), which controls for the expected proportion of false 
positives in a statistical test, was applied to adjust for multiple comparisons at a value of 0.05 
(Genovese, Lazar, & Nichols, 2002). Based on anatomical boundary schemes from FreeSurfer, 
regions of interest (ROIs) were mapped across all subjects and mean per hemisphere thickness 
values were derived. The region of interest means were then entered as dependent variables in 
analysis of variance (ANOVA) models, followed by Bonferroni post hoc comparisons. 
3. Results 
3.1 Clinically-based Subgrouping Analyses  
Of the 96 patients recruited, intellectual decline of at least 10 points from premorbid 
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levels as measured by WRAT-4 Reading occurred in approximately 20% (n=14) of the patients 
(the intellectually deteriorated group). Similarly, approximately 20% (n=14) showed low 
premorbid intellect based on WRAT-4 Reading scores, combined with low average current IQ 
(the premorbidly impaired group). Approximately 40% (n=29) of the patients were classified as 
intellectually preserved with both current and premorbid IQ based on WRAT-4 Reading scores 
within normal limits. Roughly 80% of the patient sample was captured by these 
psychometrically-defined groups. Table 3 provides the mean IQ and WRAT-4 Reading standard 
scores for patients and controls. 
3.2 Demographic Characteristics 
 Demographic characteristics of the patient groups and comparison controls are presented 
in Table 1. The patient groups ranged from 20 to 63 years of age, whereas the healthy control 
group varied from 19 to 64. All groups were predominately male and Canadian-born, with 
English as their first spoken language. There were no significant group differences in age, sex 
composition, or in years of education.  
3.3 Clinical Characteristics of Patient Groups 
Clinical characteristics of the patient groups are presented in Table 2; these include the 
PANSS subscales, ratio of inpatients in each patient group, ratio of patients with schizoaffective 
disorder in each patient group, duration of illness, and current medications. Duration of illness 
was measured from the time of each patient’s first treatment or hospitalization. On the basis of a 
χ2 analysis, diagnosis (schizophrenia vs. schizoaffective disorder) and psychiatric treatment 
(inpatient vs. outpatient) were not found to be significantly associated with the intellectual 
subgroups. As seen in Table 2, all patient groups were comprised predominantly of outpatients, 
with the average being approximately 86% (range 79-90%). The rates of schizoaffective disorder 
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were comparable across the three patient groups, with the average being approximately 44% 
(range 29-52%). Patient groups also did not differ in duration of illness, with the average being 
approximately 18 years (range 14.9-21.1 years). Finally, patient groups did not differ in 
frequency of treatment with second-generation antipsychotic medication, anti-Parkinson 
medication, antidepressant medication, anxiolytics, or lithium. At the time of testing, most 
patients (86%) were receiving atypical neuroleptic medications, usually Clozaril (clozapine), 
Risperdal (risperidone), Seroquel (quetiapine), or Zyprexa (olanzapine). Approximately 35% of 
patients were taking antidepressant medication, 28% were receiving anxiolytics, 14% were 
taking anti-Parkinson medication, and 12% were receiving lithium.  
As indicated in Table 2, a univariate F test indicated a significant main effect of Group (F 
(2, 54) = 3.67, p = .032) for the positive subscale of the PANSS. Although post hoc t tests (with 
Bonferroni adjustment) showed that patients with premorbid impairments experienced higher 
rates of positive symptoms compared to the patients with preserved abilities, this only 
approached statistical significance (p = .053). The schizophrenia patient groups did not differ 
significantly in terms of the severity of negative or general symptoms. All patient subgroups 
were also indistinguishable in activation symptoms; thought disturbance; paranoia; anergia; and 
depression (see Table 2).  
3.4 Neurocognitive Performance 
 Cognitive data for the four groups are presented in Table 3. As expected, given the basis 
for the classification scheme used to categorize patients into subgroups, there were significant 
differences in premorbid and current IQ scores as measured by the WRAT-4 and WASI, 
respectively. Bonferroni comparisons identified that patients with preserved intellect had 
significantly higher scores than patients with either deteriorated or premorbidly impaired intellect 
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for both WRAT-4 (p DP, IP < .001) and WASI IQ scores, (p DP, IP < .001). In addition, patients with 
deteriorated intellect had higher WRAT-4 scores than patients with premorbidly impaired 
intellect (p = .005).  
MCCB performance profiles of the patient and control groups are presented in Figure 1. 
As indicated in Table 3, Univariate F tests indicated a significant main effect of Group for the 
composite score of the MCCB (F (3, 89) = 70.31, p < .001) and for each domain as follows: 
Speed of Processing (F (3, 89) = 27.88, p < .001), Attention/Vigilance (F (3, 89) = 25.96, p < 
.001), Working Memory (F (3, 89) = 35.90, p < .001), Verbal Learning (F (3, 89) = 30.82, p < 
.001), Visual Learning (F (3, 89) = 27.07, p < .001), Reasoning and Problem Solving (F (3, 89) = 
22.05, p < .001), and Social Cognition (F (3, 89) = 10.78, p < .001). Compared to deteriorated 
and premorbidly impaired patients, post hoc t tests with Bonferroni adjusted p values showed 
that intellectually preserved patients achieved significantly higher scores on the composite score 
of the MCCB (p DP, IP < .001) and on six out of the seven individual domains: Speed of 
Processing (p DP = .001, p IP = .005), Attention/Vigilance (p DP, IP < .001), Working Memory (p DP, 
IP < .001), Verbal Learning (p DP, IP < .001), Visual Learning (p DP, IP < .001), and Social 
Cognition (p DP = .003, p IP = .047). Furthermore, preserved patients and healthy control 
participants did not differ on the attention/vigilance, working memory, visual learning and 
memory, and social cognition domains of the MCCB. However, preserved patients scored lower 
than the healthy control participants on the composite score of the MCCB (p < .001) and on the 
processing speed (p < .001), verbal learning and memory (p = .014), and reasoning/problem 
solving (p < .001) subscales. Patients with deteriorated and premorbidly impaired profiles were 
statistically equivalent on all MCCB indicators.  
On a test measuring biased probabilistic reasoning (Beads task), a univariate F test 
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indicated a significant main effect of Group (F (3, 89) = 4.15, p = .008). Post hoc t tests with 
Bonferroni adjusted p values showed that deteriorated patients scored lower than preserved 
patients (p = .026) and control participants (p = .039). There were no differences between 
patients with deteriorated and premorbidly impaired profiles on this task. On a test measuring an 
externalizing attribution tendency (IPSAQ), there were no significant differences between any of 
the groups. On the verbal theory-of-mind measure (Faux Pas), a univariate F test indicated a 
significant main effect of Group (F (3, 89) = 20.90, p < .001). Post hoc t tests with Bonferroni 
adjusted p values showed that deteriorated and premorbidly impaired patients scored lower when 
compared to preserved patients (p DP, IP < .001) and healthy participants (p DP, IP < .001). There 
were again no differences between patients with deteriorated and premorbidly impaired profiles 
on this task. On the visual theory-of-mind measure (Reading the Mind in the Eyes), a univariate 
F test indicated a significant main effect of Group (F (3, 89) = 39.26, p < .001). Post hoc t tests 
with Bonferroni adjusted p values showed that all patient groups scored lower than the control 
group (p PP = .03, p DP, IP < .001). However, preserved patients achieved significantly higher 
scores on this measure when compared to deteriorated and premorbidly impaired patients (p DP, IP 
< .001). There were no differences between patients with deteriorated and premorbidly impaired 
profiles on this task. 
3.5 Group Differences in Vertex-Based Cortical Thickness 
When all schizophrenia patients, regardless of their intellectual subtype classification, 
were compared to healthy control participants, statistical surface thickness maps revealed 
prominent thinning of the cortex (Figure 2). Regions included right hemisphere supramarginal 
and lateral occipital areas, as well as selective bilateral thinning in the superior, middle, and 
inferior temporal gyri. On the medial aspects, right hemisphere precuneus and bilateral lingual 
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and fusiform thinning was also present, with some mild involvement of the left posterior 
cingulate. Examination of cortical thickness mapping in preserved patients, contrasted with 
control subjects (Figure 3), revealed a pattern similar to that above. Namely, thinning in left 
hemisphere inferior parietal and fusiform regions, as well as right hemisphere supramarginal 
areas. In addition, there was bilateral thinning in the posterior cingulate and in the superior, 
middle, and inferior temporal gyri. All of these results met FDR (false-discovery rate) correction 
for multiple comparisons at a rate of p < 0.05.  
Examination of cortical thickness mapping in premorbidly impaired patients, contrasted 
with control subjects (Figure 4), revealed trend thinning in frontal and temporal regions; 
however, these differences did not survive FDR correction for multiple comparisons. Initial 
examination of cortical thickness mapping contrasting the three patient groups revealed mild 
thinning in different brain regions, but none survived FDR correction for multiple comparisons, 
indicating a lack of significant vertex-wise cortical thinning between these three patient groups. 
Uncorrected statistical maps revealed trend cortical thinning between the deteriorated and 
premorbidly impaired patient groups (Figure 5) in frontal and temporal regions, but none of these 
findings survived FDR correction for multiple comparisons.  
3.6 Group Differences in ROI-based Cortical Thickness 
The widespread thinning pattern in schizophrenia patients (Figure 2) was used as the 
basis for a focused ROI approach. Comparison of thickness values within the thinning pattern 
ROIs revealed several significant differences between groups (Table 4). For preserved patients 
and controls, significant differences were evident in the right superior temporal sulcus (p = .017), 
left fusiform gyrus (p = .004), and right frontal pole (p = .013), as well as in bilateral inferior 
parietal cortex (p Right = .026; p Left = .030), middle temporal gyri (p Right = .002; p Left = .002), and 
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supramarginal areas (p Right = .002; p Left = .035). For premorbidly impaired patients and controls, 
significant differences were noted in the right superior temporal sulcus (p = .032), inferior 
parietal lobule (p = .041), middle temporal gyrus (p = .025), and precuneus (p = .047), as well as 
bilateral fusiform regions (p Right = .031; p Left = .003). For deteriorated and preserved patients, 
significant differences were evident in the left lateral orbitofrontal cortex (p = .012) and the pars 
triangularis of the inferior frontal gyrus (p = .017). The deteriorated and premorbidly impaired 
patients differed in only one area, the left pars triangularis of the inferior frontal gyrus (p = 
.029).  
Discussion 
There is increasing consensus that schizophrenia is not a single disease, but rather a 
collection of several overlapping illnesses. Although most patients demonstrate a generalized 
deficit across multiple cognitive domains assessed by widely used clinical neuropsychological 
measures, there is extensive variability in the extent of impairment. Thus, several attempts have 
been made to organize the illness into more homogeneous groups of patients, with hopes of 
providing insight to a more accurate definition of schizophrenia. The aim of the present 
investigation was to identify and estimate the prevalence of intellectual performance patterns 
corresponding to preserved, deteriorated, and premorbidly impaired ability, and to examine the 
value and validity of this approach for reducing the heterogeneity of schizophrenia. The 
intellectual subtypes were compared on independent adjunct measures of cognitive ability and 
symptom profile and severity. Neuroanatomical characteristics of these subtypes were also 
investigated in order to better understand the relationship between intellectual or cognitive 
impairment and neuropathology in schizophrenia.  
The findings of the present investigation confirm previous research demonstrating three 
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distinct neuropsychological profiles in schizophrenia and may provide further insight into the 
developmental processes involved. On the basis of widely used indicators of current and 
premorbid IQ, this study successfully identified the proposed intellectual subtypes; one 
representing preserved intellectual ability (i.e., preserved patients; PP), another representing a 
deteriorated pattern (i.e., deteriorated patients; DP), and a third representing a premorbidly 
impaired patient group (i.e., impaired patients; IP). Roughly 80% of the patient sample was 
distributed across these psychometrically-defined groups. Approximately 40% of the patient 
sample was identified as being intellectually preserved, which is consistent with the percentages 
found in some other studies. Using similar means of estimating current and premorbid IQ to 
identify schizophrenia patients as being intellectually preserved, several investigations reported a 
25-40% overall prevalence of intellectual preservation in schizophrenia (Ammari et al., 2014; 
Badcock et al., 2005; Weickert et al., 2000; Wells et al., 2015). The intellectually deteriorated 
subtype constituted approximately 20% of the original patient sample, which is somewhat lower 
than the 25-50% overall prevalence found in some other studies (Ammari et al., 2014; Badcock 
et al., 2005; Weickert et al., 2000; Wells et al., 2015). The reason for the discrepancy is unclear 
given that similar classification criteria and means of estimating current and premorbid IQ were 
utilized in this study. There is also no reason to suspect that the sample is not representative of 
the schizophrenia patient population since similar prevalence rates of intellectual preservation 
reported by other investigators were observed in this study. Further, total patient mean IQ of 
approximately 89 in this study is consistent with others, and the sex ratios are also similar to 
those reported by others (Ammari et al., 2014; Lieberman et al., 1992; Mortensen et al., 1999). 
Finally, the premorbidly impaired subtype also constituted approximately 20% of the original 
patient sample, which is consistent with the percentages found by other investigators (Ammari et 
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al., 2014; Badcock et al., 2005; Weickert et al., 2000; Wells et al., 2015). Inevitably, the findings 
of this study will pertain to only a subset of patients, reflecting the inherent heterogeneity of the 
schizophrenia diagnosis. Nevertheless, a considerable proportion of the original patient sample, 
approximately 80%, was captured by this intellectual typology.  
Preserved Group 
The data of the present investigation provide partial validation of the three proposed 
intellectual subtypes as distinct illness variants. In keeping with prior studies, the results confirm 
the existence of a subgroup of schizophrenia patients with preserved intellectual abilities. 
Intellectually preserved patients reported similar levels of symptom severity relative to 
intellectually deteriorated and premorbidly impaired patients. This was the case across all 
symptom indicators including positive, negative, and general symptoms. Intellectually preserved 
patients were also indistinguishable from the other patient subtypes in activation symptoms; 
thought disturbance; paranoia; anergia; and depression. This suggests no attenuation of the 
psychotic process in these patients.  
The abilities of intellectually preserved patients in several aspects of cognition (e.g., 
attention, working memory, visual learning and memory, and verbal measures of social 
cognition) approximated those of healthy adults. However, this preserved intellectual ability 
level did not associate with complete normality of cognitive skills. The preserved patients scored 
lower than the healthy control participants on indictors of processing speed, verbal learning and 
memory, reasoning/problem solving, and on a visual theory-of-mind measure. Nevertheless, 
intellectually preserved patients did show an advantage relative to more typical patients (i.e., 
patients with deteriorated or premorbidly impaired intellect) on indicators of processing speed, 
attention, working memory, verbal learning and memory, visual learning and memory, and social 
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cognition including theory-of-mind. This suggests that intellectual preservation in schizophrenia 
associates with significantly better cognitive ability across multiple domains. The only exception 
was on a test measuring reasoning and problem solving (‘Mazes’ task), in which there were no 
significant differences between the patient groups. The lack of between-group differences among 
patients on the reasoning/problem solving domain of the MCCB may be explained by reduced 
sensitivity of the ‘Mazes’ task to executive dysfunction. Consistent with this, other investigators 
found that this domain does not appear to be sensitive to impairment in schizophrenia patients as 
it has the smallest between-group differences when compared to controls (Gray et al., 2013). 
Other measures of problem solving, such as the Wisconsin Card Sorting task, often engender 
evidence of a greater gap between schizophrenia patients and controls. Intellectually preserved 
patients also outperformed those with a deteriorating pattern on a measure of probabilistic 
reasoning, suggesting that they are less likely to ‘jump to conclusions’ prematurely. Therefore, 
chronic schizophrenia can exist in the context of preserved general intellectual ability and at least 
some additional aspects of cognition. 
In terms of biological validity, cortical thickness mapping in intellectually preserved 
patients revealed a pattern of widespread thinning in the cortex when compared to healthy 
control participants. More specifically, there was significant thinning in left hemisphere inferior 
parietal and fusiform regions, as well as right hemisphere supramarginal areas. Furthermore, 
there was bilateral thinning in the posterior cingulate and in the superior, middle, and inferior 
temporal gyri. When a focused ROI approach was employed, significant differences were 
evident between preserved patients and controls in the right superior temporal sulcus, left 
fusiform gyrus, and right frontal pole, as well as in bilateral inferior parietal cortex, middle 
temporal gyri, and supramarginal areas. Notably, this pattern of thinning was similar to that 
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observed in the other patient groups. 
When intellectually preserved patients were compared to the other patient groups, 
differences emerged between the preserved and deteriorated patients in the left lateral 
orbitofrontal cortex and the pars triangularis of the inferior frontal gyrus. There were no 
significant differences between the preserved and premorbidly impaired patient groups.  That the 
premorbidly impaired group demonstrates no neurobiological differences from the preserved 
group, yet significantly differs from them on most cognitive measures is surprising. Indeed, one 
would expect the biggest differences between these two groups given their markedly distinct 
cognitive profiles. Nevertheless, uncorrected contrast maps for these comparisons suggest trend 
differences, indicating subtle characteristics unique to these groups may exist. 
Deteriorated Group 
The findings of this study also support the existence of a subgroup of schizophrenia 
patients displaying a general intellectual decline from estimated premorbid levels based on 
WRAT-4 Reading scores. This diminution was obtained in only 20% of patients in this sample. 
In terms of symptom profile, patients with deteriorated intellect reported similar levels of 
symptom severity compared to the other patient subtypes. Cognitively, patients with this 
deteriorated intellectual pattern performed lower than healthy control participants on all 
measures of neurocognitive functioning assessed. They were also significantly impaired relative 
to intellectually preserved patients on all cognitive measures with the exception of reasoning and 
problem solving (‘Mazes’ task). They were also disadvantaged relative to preserved patients on 
specialized cognitive neuropsychiatry tests tapping biased reasoning and theory-of-mind. Unlike 
previous findings, intellectual decline appears to affect all cognitive domains equally in this 
study. Weickert and colleagues (2000) found that intellectual decline observed in the deteriorated 
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patient group was implicated with frontotemporal dysfunction in that patients had impairments in 
memory, executive function, and attention. In this study, intellectual decline was also associated 
with deficits in processing speed and social cognition. Compared to patients with premorbid 
impairments, they were indistinguishable on all domains of neurocognitive functioning assessed, 
including specialized cognitive neuropsychiatry tests tapping biased reasoning and theory-of-
mind.  
Regarding biological validity, cortical thickness mapping in intellectually deteriorated 
patients revealed a pattern of widespread thinning in the cortex similar to that seen in the other 
patient groups when they were compared to healthy control participants. When compared to 
premorbidly impaired patients, uncorrected statistical maps revealed trend cortical thinning in 
frontal and temporal regions, but none of these findings survived FDR correction for multiple 
comparisons. When a focused ROI approach was employed, the deteriorated and premorbidly 
impaired patients differed in only one area, the left pars triangularis of the inferior frontal gyrus. 
As stated above, significant differences were evident between deteriorated and preserved patients 
in the left lateral orbitofrontal cortex and the pars triangularis of the inferior frontal gyrus.  
Premorbidly-Impaired Group  
Finally, the findings support the existence of a subgroup of schizophrenia patients having 
a premorbid intellectual impairment with no evidence of disease-related decline following the 
onset of illness. This suggests that their intellectual deficit is not attributable to symptom onset or 
diagnosis. In terms of symptom expression, this patient subtype did not associate with a unique 
clinical profile as similar levels of symptom severity were reported by these patients compared to 
the other patient subtypes. From a cognitive standpoint, patients with this premorbidly impaired 
intellectual pattern performed lower than healthy control participants on all measures of 
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neurocognitive functioning assessed. They were also significantly compromised relative to 
intellectually preserved patients on most measures of cognitive functioning assessed; the only 
exception being reasoning and problem solving. Further, they were disadvantaged relative to 
preserved patients on specialized theory-of-mind tests. Compared to patients displaying a pattern 
of deteriorated intellect, they were indistinguishable on all domains of neurocognitive 
functioning, including specialized cognitive neuropsychiatry tests tapping biased reasoning and 
theory-of-mind.  
In terms of biological validity, cortical thickness mapping in premorbidly impaired 
patients revealed trend thinning in frontal and temporal regions when compared to healthy 
controls, but none of these findings survived FDR correction for multiple comparisons. When a 
focused ROI approach was employed, significant differences were noted in the right superior 
temporal sulcus, inferior parietal lobule, middle temporal gyrus, and precuneus, as well as 
bilateral fusiform regions. When premorbidly impaired patients were compared to the other 
patient groups, uncorrected statistical maps revealed trend cortical thinning between the 
premorbidly impaired and deteriorated patient groups in frontal and temporal regions, but again 
none of these findings survived FDR correction for multiple comparisons. When a focused ROI 
approach was employed, the premorbidly impaired and deteriorated patients differed in only one 
area, the left pars triangularis of the inferior frontal gyrus.  
Cognitive and Symptom Validity of the Intellectual Subtypes 
Demonstrating the value and construct validity of particular psychometric performance 
patterns is particularly challenging for investigators attempting to reduce the heterogeneity of the 
schizophrenia diagnosis by identifying more homogeneous groups of patients. It appears that the 
criteria utilized in this study for defining intellectual preservation in schizophrenia produced a 
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partially valid subgroup. Intellectually preserved patients were indistinguishable from healthy 
control participants on a number of neurocognitive measures assessed, including attention, 
working memory, visual learning and memory, and social cognition. However, they scored lower 
than controls on indictors of processing speed, verbal learning and memory, and 
reasoning/problem solving. This is consistent with previous reports in which direct comparison 
with healthy control participants has often found disparities in certain abilities including 
abstraction and executive functioning (Allen et al., 2003; Kremen et al., 2000; Weickert et al., 
2000) and attention (Kremen et al., 2001). Indeed, some have concluded that executive 
dysfunction often coexists with preserved IQ and may constitute a “necessary type of cognitive 
impairment in schizophrenia” (Weickert et al., 2000). There is also a longstanding notion in the 
literature that reduced processing speed is a characteristic feature of schizophrenia that does not 
preclude relatively preserved performance on IQ measures (Badcock, Williams, Anderson, & 
Jablensky, 2004; Dickinson et al., 2008; Pantelis et al., 1997; Hartman, Steketee, Silva, Lanning, 
& McCann, 2002; Vaskinn et al., 2014; Vinogradov et al., 2003; Wilk et al., 2005). Therefore, 
the findings from this study lend support to the idea that cognitive impairment is a core feature of 
schizophrenia present to some degree in all patients, regardless of whether or not intellectual 
abilities are preserved. Thus, using neurocognition as a biomarker in genetic studies is warranted. 
In terms of psychopathological validity, intellectually preserved patients reported similar levels 
of symptom severity relative to intellectually deteriorated and premorbidly impaired patients, 
suggesting that improved intellect and cognition do not associate with a symptomatically milder 
form of the disease.  This is inconsistent with other studies showing that patients in the preserved 
group show less negative symptoms than their impaired counterparts (Donohoe et al., 2006; 
MacCabe et al., 2012; Wells et al., 2015). 
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The case for the deteriorated and premorbidly impaired groups as distinct illness variants 
is more equivocal and cannot be determined definitively using the available data. There was no 
evidence that these two intellectual patterns map onto current clinical or neuropsychological 
status. The deteriorated and premorbidly impaired groups were statistically equivalent on all 
clinical and neurocognitive measures assessed. Indeed, the evidence strongly suggests that 
patients in the deteriorated and premorbidly impaired groups are better represented by one 
intellectually/cognitively impaired illness variant. Therefore, it may be more useful to collapse 
rather than separate these patient groups. One explanation for their resemblance may be that the 
reading-IQ ratios utilized in this study are simply non-pathological psychometric artifacts that 
also occur in healthy populations. Indeed, previous research found that the deteriorated pattern 
does in fact exist in the general population. For example, Ammari and colleagues (2014) found 
that approximately 11% of their healthy control sample showed the average reading-below 
average IQ “deterioration” profile. Therefore, premorbid-current IQ discrepancies may signify 
differential patterns of intellectual development and present capacity that are not unvaryingly or 
intrinsically pathological and without direct consequences for more comprehensive 
neurocognitive functioning. Therefore, although it is well established that the extent of cognitive 
dysfunction or relative absence of any cognitive impairment is a characterizing aspect of the 
schizophrenia illness, patient subgroups distinguished on the basis of reading and IQ scores may 
not reduce or help advance the heterogeneity issue in schizophrenia.   
An alternative explanation for the equivalence between the deteriorated and premorbidly 
impaired groups is that a neurodevelopmental mechanism still underlies the cognitive 
impairments observed in the deteriorated subtype, since discreet neurodevelopmental alterations 
may pave the way for delayed psychiatric disturbance and cognitive deficits (Weinberger, 1987). 
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Indeed, one may propose several theoretical neurodevelopmental courses that ultimately give rise 
to the cognitive impairments observed in schizophrenia, including those in intelligence. One 
trajectory may be exemplified by profound and pervasive cognitive impairment discernible from 
early development long before the onset of any psychotic symptoms. Both the deteriorated and 
premorbidly impaired groups may follow that trajectory, albeit the former may be characterized 
by more subtle neurodevelopmental changes and may donate the appearance of deterioration 
coinciding with psychotic symptom onset. The preserved patient group may constitute a discrete 
subgroup of patients within the schizophrenia patient population who have suffered less 
neurodevelopmental damage than other more typically impaired patients (MacCabe, Aldouri, 
Fahy, Sham, & Murray, 2002; Murray, O'Callaghan, Castle, & Lewis, 1992). As a result, they 
have milder cognitive impairments, seemingly limited to the domains of processing speed, verbal 
learning and memory, and reasoning/problem solving. It is indeterminate at this time whether 
these impairments occur prior to or concur with the onset of psychotic symptoms.  
Neurobiological Validation of the Intellectual Subtypes 
As previously mentioned, only a small number of studies have investigated differences in 
the brain structure of subgroups in schizophrenia grouped according to neuropsychological 
profiles, and almost no available data bears on the neurobiological validity of the proposed 
intellectual subtypes. Biological validation of the proposed intellectual subtypes requires the 
demonstration that differences in intellectual patterns between the patient groups correspond to 
neurobiological differences. Woodward and Heckers (2015), the only study of brain structure 
abnormalities in intellectually-defined subgroups of schizophrenia patients, found that those with 
below-average estimated premorbid ability exhibit evidence of early cerebral hypoplasia, 
whereas intellectually preserved and deteriorated patients show evidence of brain tissue loss 
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consistent with progression or later cerebral dysmaturation. However, this study did not include 
an analysis of cortical thinning patterns in the proposed intellectual subgroups.  
In the present study, the findings are consistent with previous reports that structural 
aspects of the cerebral cortex distinguish schizophrenia patients from healthy control 
participants. On the other hand, the neurobiological evidence bearing on the validity of the 
proposed intellectual subtypes is feeble. Although some trend differences emerged, the overall 
cortical thinning pattern was largely similar across the intellectual subtypes. Therefore, cortical 
thinning across the brain appears to reflect a shared disease process in schizophrenia with no 
association to intellectual or cognitive profile. Consequently, it is likely that a mutual neural 
mechanism begets the clinical symptoms in schizophrenia and that a separate mechanism 
underlies cognitive task performance (Dominguez et al., 2009). Specifically, the data does not 
support the notion that intellectually preserved patients may be a distinct subgroup within the 
schizophrenia patient population since they share a similar widespread cortical thinning pattern 
with more typical patients (i.e., those with deteriorated or premorbidly impaired intellect) when 
compared to healthy control participants. Therefore, the intellectually preserved subtype appears 
to be an aggregate of patients with less severe cognitive impairments; however, this cognitive 
advantage does not extend to a milder neurobiological form of the disorder evidenced by less 
marked neurobiological abnormalities than those observed in patients with deteriorated and 
premorbidly impaired intellect. This in inconsistent with other studies showing that cortical 
thinning is minimal in patients with normal or near-normal cognitive performance (Cobia et al., 
2011). 
The case for the deteriorated and premorbidly impaired groups as biologically distinct 
illness variants is even weaker. Although uncorrected statistical maps revealed trend cortical 
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thinning between the deteriorated and premorbidly impaired patient groups in frontal and 
temporal regions, none of these findings survived FDR correction for multiple comparisons. 
When a focused ROI approach was employed, the deteriorated and premorbidly impaired 
patients differed in only one area, the left pars triangularis of the inferior frontal gyrus, a region 
associated with the cognitive control of memory and in the semantic processing of language 
(Badre & Wagner, 2007; Mainy et al., 2007). Wisco and colleagues (2007) presented data 
showing that the pars triangularis specifically was highly distorted in schizophrenia patients 
compared with demographically matched control participants. They asserted that Broca’s area is 
an especially plastic region of the brain in that its morphology can change dramatically from 
childhood to adulthood. This would be consistent with the notion that a neurodevelopmental 
mechanism underlies the cognitive impairments observed in the premorbidly impaired patient 
group. Nevertheless, despite this one difference, comprehensive neuroanatomical data provide 
little support for the distinctiveness of deteriorative relative to premorbid intellectual 
compromise. 
IQ as a normality criterion  
A complicating factor in the study of cognitive subtypes in schizophrenia is the nature of 
the criteria utilized to denote cognitive normality or preservation. It is well established that 
schizophrenia can occur in the relative absence of cognitive impairment in a minority of patients; 
however, definitions of cognitive normality in the literature are inconsistent and controversial. IQ 
is a universally used measure and one of the most often utilized methods for defining normality 
(e.g., Kremen et al., 2001). However, summary indices like IQ may be overly restrictive since 
they are obtained by collapsing across a number of subtests, likely concealing cognitive strengths 
and weaknesses in patients relative to healthy control participants (Wilk et al., 2005).  The fact 
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that preserved patients still demonstrate deficiencies in processing speed, verbal learning and 
memory, and reasoning/problem solving when compared directly with healthy control 
participants suggests that general intellectual ability fails to capture the true breadth of cognitive 
impairment expressed in schizophrenia. Others have also found that patients show evidence of 
greater neuropsychological impairment than what would be expected based solely on their IQ 
(e.g., Gray et al., 2013; Vaskinn et al., 2014). It has been argued that more broadly-based 
measures should be used to determine cognitive normality instead. For example, when the 
MCCB composite score is used as a normality criterion, no subtest profile differences are found 
between cognitively normal schizophrenia patients and healthy controls (Muharib et al., 2014).    
Cognition and Psychopathology 
Impaired cognition is highly prevalent in schizophrenia and seen as a core feature of the 
illness, and the relationship between cognition and psychopathology has been extensively 
studied. Consistent with many reports in the literature (e.g., Dibben et al., 2009; Nieuwenstein, 
Aleman, & de Haan, 2001), data from the present investigation support the notion that cognitive 
ability and symptom severity represent distinct and dissociable comorbidities or independent 
disease processes in schizophrenia patients. There were no significant differences in the severity 
of symptoms between patients with generalized cognitive deficits (deteriorated or premorbidly 
impaired groups) and those with more limited cognitive impairments (preserved group). 
Therefore, it is possible for patients with preserved intellectual functioning and limited cognitive 
dysfunction to experience elevated as well as mild positive and negative symptoms. 
Contrariwise, patients with more typical generalized intellectual and cognitive deficits may also 
experience mild or severe symptoms. Indeed, in this study, there is no compelling evidence that 
any aspect of the clinical illness varies with intellectual or cognitive profile, including illness 
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duration, medication differences, or rates of schizoaffective disorder. The neurobiological data 
also support the notion that psychopathology and impaired cognitive functions are facilitated by 
dual and independent pathologies. Indeed, cortical thinning across the brain appears to reflect the 
shared psychotic disease process in schizophrenia, whether or not it is accompanied by 
impairment in the intellectual or cognitive functions assessed by standard performance tasks. 
Consequently, alternative indicators of neural structure and function should be considered in 
order to map theoretically useful cognitive-behavioral differences onto parallel 
pathophysiologies and etiologies. 
In keeping with these findings, a large body of evidence suggests weak or absent 
relationships between the symptomatic and cognitive dimensions of the disorder. More 
specifically, several investigators have reported no significant differences in positive and 
negative symptom severities between patients with intellectual or cognitive impairments and 
patients with relatively normal intellect or cognition (Ammari et al., 2014; Holthausen et al., 
2002; Kremen et al., 2000; Palmer et al., 1997; Vaskinn et al., 2014). More recent reviews have 
substantiated previous reports that associations between psychopathology, especially psychotic 
symptoms, and many standard cognitive tasks used in clinical neuropsychology, are 
unimpressive and often absent in schizophrenia
 
(Berenbaum et al., 2008; Dibben et al., 2009; 
Dominguez et al., 2009). However, these findings contradict numerous studies linking low IQ or 
cognitive impairment with negative symptoms (e.g., Aleman et al., 1999; Ammari et al., 2010; 
Basso et al., 1998; Cameron et al., 2002; Cobia et al., 2011; Leeson et al., 2010; Moritz et al., 
2001; Nieuwenstein et al., 2001; Stirling, Hellewell, & Hewitt, 1997; Wells et al., 2015). The 
discrepancy in findings may reflect in part the multiplicity of measures used by researchers to 
examine IQ or cognitive performance and illness symptoms. Numerous tests and protocols are 
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utilized with patients with schizophrenia, and it is possible that different measures may be 
assessing somewhat different facets of the same domain (Vaz & Heinrichs, 2002).  
Furthermore, the association between the severity of general psychiatric symptoms and 
cognitive deficits in schizophrenia has attracted considerable interest in recent years. Several 
investigators reported that depressive symptoms relate significantly to cognitive test performance 
(e.g., Brébion, Smith, Amador, Malaspina, & Gorman, 1997; Holthausen, Wiersma, Knegtering, 
& Van den Bosch, 1999). In contrast to this finding, the severity of depressive symptoms was 
equivalent in this study between patients with generalized cognitive deficits (deteriorated or 
premorbidly impaired groups) and those with more limited cognitive impairments (preserved 
group). Ammari and colleagues (2014), the only study that has examined the symptom profiles 
of the proposed intellectual subtypes, also reported equivalent rates of general psychiatric 
symptoms including depression. The depression equivalence across the intellectual subtypes is 
important because it suggests that IQ profiles and cognitive impairments in schizophrenia are not 
reducible to the attenuating effects of depression. Overall, this study supports the view that IQ 
status/cognitive performance and psychopathology are independent in schizophrenia.  
Implications 
The study of intellectually preserved patients with schizophrenia offers a unique window 
into the intricacies of the illness and may impart valuable information on both the worth and 
limits of improved cognitive function in the schizophrenia patient population. Indeed, one of the 
main incentives for understanding the signature of cognitive impairment in schizophrenia is the 
relationship between cognitive performance, functional skills, and functional outcome (Bowie & 
Harvey, 2005). It has been suggested that enhancement in disease-related cognitive impairments 
(e.g., working memory and attention, learning, etc.) may produce a wide range of benefits in 
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real-world living for patients suffering from this disabling form of mental illness (Green et al., 
2004). Intact social cognition has also been shown to be associated with better daily living skills 
and community adjustment in patients with schizophrenia (Brekke, Kay, Lee, & Green, 2005; 
Couture, Penn, & Roberts, 2006; Sergi et al., 2007). Correspondingly, the National Institute of 
Mental Health – Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(NIMH-MATRICS) initiative is striving to produce an evaluative framework and instrument 
base that will endorse and encourage the introduction of a new class of cognitively-enhancing 
medications in schizophrenia. Indeed, cognitive impairments are now viewed as principal targets 
of both rehabilitative/remediation and psychopharmacological treatment (Gold, 2004; Marder, 
2006a, 2006b, 2006c; Marder & Fenton, 2004; McGurk, Twamley, Sitzer, McHugo, & Mueser, 
2007; Reeder, Newton, Frangou, & Wykes, 2004; Stone & Seidman, 2008). The logic behind 
this initiative is that improving a patient’s cognitive status should result in meaningful changes 
and enhancements in functional status and adjustment. In the present study, the abilities of 
intellectually preserved patients on tests of attention, working memory, and social cognition 
approximated those of healthy adults. Therefore, one may argue that these patients allow for the 
unique opportunity to view the upper limit of functionality that can potentially be acquired from 
these proposed medications.  
In addition, subtyping based on neuropsychological data in schizophrenia has important 
practical implications since more refined behavioural profiles may be relevant to clinical 
management, cognitive enhancement, and rehabilitation, both for new intake and existing 
patients with schizophrenia. For example, in view of mounting evidence that IQ and cognitive 
performance are associated with enhanced ability to manage the responsibilities and stressors of 
daily living and better overall outcome (e.g., Leeson, Barnes, Hutton, Ron, & Joyce, 2009; Wells 
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et al., 2015), intellectual preservation may be viewed as a protective factor and may prove to be a 
positive prognostic marker for the long-term functional outcome status of schizophrenia patients. 
Although research has shown that intellectually preserved patients do not show complete 
normalization of real world adjustment, these patients are advantaged relative to intellectually 
impaired patients in both life skills and several key indicators of real-world functioning, 
including support utilized in the community (Ammari et al., 2010, 2014). Reducing the amount 
of support required by each patient with schizophrenia not only improves their ability to live 
independently in the community, but it also helps lessen the stigma and financial burden of the 
illness through decreased dependence on community supports. On the other hand, intellectual or 
cognitive impairment may be used as a vulnerability or negative prognostic marker for the 
functional outcome status of schizophrenia patients.  
Overall, knowledge of the intellectual or cognitive status of patients would assist in 
developing individualized treatment plans that would maximize a patient’s independent 
functioning potential and in tailoring enhancement medications to improve very specific aspects 
of cognition. For instance, it has been suggested that list learning and working memory are 
amenable to pharmacological and other interventions. Patients with deteriorated and premorbidly 
impaired intellectual patterns also have impairments in learning and working memory 
functioning. Hence, identifying these patients as distinct treatable groups is certainly worthwhile. 
Moreover, there is evidence that high premorbid intellectual ability may reduce the risk of 
developing schizophrenia-spectrum disorders (Reichenberg et al. 2006a, 2006b; Seidman, 
Bukka, Goldstein & Tsuang, 2006).  Conversely, low intellectual functioning is a risk factor for 
schizophrenia and schizophrenia-spectrum disorders (Reichenberg et al., 2006a, 2006b; Seidman 
et al., 2006). Therefore, premorbid intellectual ability and individual strengths and weaknesses in 
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cognitive functioning should be assessed in the context of prevention efforts for high risk 
individuals and in developing or selecting appropriate treatment and rehabilitation services for 
schizophrenia patients. 
Limitations 
There are several limitations to the present study. First, the numbers of patients in the 
deteriorated and premorbidly impaired subtypes were relatively small, resulting in low power for 
the statistical analyses as only medium-to-large group effects were most likely to reach statistical 
significance. Consequently, it is possible that there were significant group differences that were 
not exposed as detecting small-to-medium effect sizes will require larger sample sizes. Future 
studies would benefit from recruiting more patient and comparison control participants (e.g., 
minimum of n = 200, 100, respectively), which would hopefully result in twice the number of 
patients in each of the subtypes, and allow investigators to determine more precisely the nature 
of the clinical, cognitive, and neurobiological validity of the subtypes. 
Second, premorbid IQ scores were not obtained directly as the design of this study was 
cross-sectional rather than longitudinal. Although the WRAT is a validated measure of 
premorbid IQ, an actual premorbid IQ measure may more accurately classify patients, especially 
cases of extreme in scores. Undoubtedly, the most convincing argument for intellectual decline 
following the onset of schizophrenia would include the use of retrospective premorbid IQ 
estimates such as scores from school-, recruit-, or clinic-based testing. In addition, it is possible 
that the current IQ score obtained using the two-subtest WASI does not provide an adequate 
measure of current general intellectual ability. The results may be different if a more 
comprehensive measure of general intellectual ability was utilized. 
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Third, although the MCCB taps a number of cognitive domains deemed relevant in the 
study of cognition in schizophrenia, the possibility remains that intellectually preserved patients 
may have more impairments of cognitive abilities not assessed by the battery utilized in this 
study.  It is also possible that intellectually preserved patients would show cognitive deficits on 
measures more sensitive to specific cognitive impairments. Other investigators have used the 
complete Wechsler Adult Intelligence Scale (WAIS) as well as the Wechsler Memory Scale 
(WMS) among other standard measures and test batteries (Allen et al., 2003; Kremen et al., 
2000; Palmer et al., 1997; Wilk et al., 2005). Further study is needed to determine the specific 
components of cognitive processing that are abnormal in these patients. Fourth, it is unclear to 
what extent the proposed intellectual patterns also occur in healthy populations, possibly 
indicating natural psychometric score differences and ability profiles that are not unvaryingly 
pathological in nature. Indeed, some investigators have identified approximately equal 
proportions of participants meeting the ‘deteriorated’ pattern in both their schizophrenia and 
healthy control samples (Ammari et al., 2014; O’Conner et al., 2012).  
A final limitation concerns the dimensionality vs. categorical view of mental illness. 
Several arguments for and against schizophrenia being a homogeneous single disease with 
varying levels of impairment have been put forth. Advocates for heterogeneity argue that genetic 
findings reject the parsimonious hypothesis that all schizophrenia is caused by the same pattern 
of genetic mutations, birth complications and viral infections (Jablensky, 2006). In addition, they 
cite evidence for several subtypes of schizophrenia linked to identifiable chromosome 
abnormalities (e.g., Chiu et al., 2002; Horowitz, Shifman, Rivlin, Pisanté, & Darvasi, 2005; 
Kendler et al. 2000; Liu et al., 2002a, 2002b). Therefore, patients with distinct intellectual 
abilities differ in their cognitive capabilities because they have fundamentally distinct illnesses 
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with differing underlying pathophysiologies and correspondingly distinct effects on brain 
structure and function. On the other hand, advocates for homogeneity argue that there are no 
disease entities in psychiatry; only continua of variation (Crow, 1995). Even when the etiology 
of a disorder is known and is unitary, the manifestation and outcome may be surprisingly varied 
(Jablensky, 2006). Therefore, phenotypic variation in schizophrenia is compatible with 
etiological homogeneity in that it reflects a continuum of severity in which patients vary along 
clinical, cognitive, and neurobiological dimensions (Cardno & Farmer, 1995; Goldberg & 
Weinberger, 1995). Accordingly, the differing cognitive abilities in those patients who are 
intellectually preserved compared with those with deteriorated or premorbidly impaired intellect 
could stem from variation in the severity of a single disease process. In other words, the disparity 
between these patient subtypes could be an artificial differentiation on a severity continuum. This 
would suggest that patients with preserved intellect are less severely affected but still exhibit 
markers of cognitive impairment in some domains or even exhibit these at a subclinical level. 
The possibility that the intellectual subtype distinctions are in actuality a question of the relative 
extent of impairment in diverse processes influencing distinct neural mechanisms rather than 
pure and biologically distinct subtypes cannot be completely excluded based on the available 
data. Therefore, the intellectually preserved subtype may not constitute a distinct subgroup, but 
rather it may represent a group of patients with less severe cognitive impairments and potentially 
less marked neurobiological manifestations compared with the deteriorated and premorbidly 
impaired subtypes.  
Conclusions 
The data of the present investigation bring back to center stage the fundamental question 
of phenotypic and etiological heterogeneity in schizophrenia. The heterogeneity vs. homogeneity 
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debate and the likely existence of etiologically diverse subtypes in schizophrenia dates back to 
the inception of the diagnostic concept and is far from over. Collectively, the results of the 
present investigation provide additional evidence that patients with schizophrenia can be 
meaningfully categorized into subtypes based on the intellectual profiles they exhibit. In other 
words, neurocognitive subtyping may be effective in organizing and reducing the heterogeneity 
of schizophrenia. More specifically, there are pronounced differences between the intellectually 
preserved and intellectually impaired patients, the latter including both the deteriorated and 
premorbidly impaired groups combined. This suggests that groups defined by intellectual 
preservation versus impairment may represent two neurobiologically distinct subgroups. The 
findings of this study have implications for addressing the heterogeneity of schizophrenia, which 
remains a major barrier to significant scientific progress in this field. Some patients may have 
impairment of a primary process which results in extensive deficits in multiple domains of 
cognitive performance, while others may have impairment of a specific process which results in 
selective performance deficits. Individual differences in intellectual or cognitive performance 
may thus be extremely valuable in classifying patients into distinct subtypes with more 
homogeneous pathophysiologies.  
Further investigation of the classification scheme used in this study is warranted in order 
to help elucidate the relationship between cognitive and neurobiological features in 
schizophrenia, and facilitate the investigation of disease heterogeneity. These distinctions could 
be an essential step leading to more valid intermediate phenotypes for genetic and 
neurobiological studies. Although some differences in cortical thickness were found in the 
proposed subtypes, larger group sizes may lead to further evidence that these subtypes represent 
neurobiologically distinct subpopulations within schizophrenia. The promise of this approach in 
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the study of illness heterogeneity in schizophrenia would be strengthened by evidence that these 
intellectual subgroups differ biologically from the rest of the patient population. Such 
distinctions could be an essential first step leading to a much more informed search for specific 
pathogenetic pathways and genetic mechanisms that underlie the illness. Clearly, this is an area 
that warrants further investigation using larger samples and the application of other 
neuroimaging and histochemical techniques along with longitudinal research designs. 
Importantly, the longitudinal stability of these cognitive subtypes across months and years and 
different treatment regimens is unknown and thus requires future study. Nonetheless, the 
findings of the present investigation are encouraging and must be replicated and complemented 
with additional cognitive, clinical, and neurobiological data. The mapping of a clinical syndrome 
onto distinct neuropsychological subtypes corresponding to distinct brain pathophysiologies is 
becoming possible and the ensuing discoveries may in the future significantly transform the 
present nosology. 
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Table 1.  
 
Demographic Characteristics of Schizophrenia and Healthy Participant Groups 
____________________________________________________________________________________________________ 
 
Variable 
 
 
PP 
(n = 29) 
 
 
DP 
(n = 14) 
 
 
IP  
(n = 14) 
 
 
PC  
(n = 36) 
 
 
Statistic 
 
 
 
 
p 
Age, years (M, SD) 39.6 (10.3) 41.4 (9.8) 42.9 (10.6) 40.3 (13.8) F3, 89 = 0.27 n.s. 
 
Sex (males)  
 
18 (62%) 
 
6 (43%) 
 
10 (71%) 
 
21 (58%) 
 
χ2 = 2.52 
 
n.s. 
 
Education, years (M, SD) 
 
Birth Country (Canada) 
 
13.5 (2.2) 
 
25 (86%) 
 
12.8 (2.5) 
 
13 (93%) 
 
11.8 (1.9) 
 
11 (79%) 
 
13.5 (2.0) 
 
33 (92%) 
 
F3, 88 = 2.54 
 
χ2 = 2.06 
 
n.s. 
 
n.s. 
 
First language English  
 
 
26 (90%) 
 
 
13 (93%) 
 
 
12 (86%) 
 
 
36 (100%) 
 
 
χ2 = 4.65 
 
 
n.s. 
 
____________________________________________________________________________________________________ 
Note: PP = Preserved Patients; DP = Deteriorated Patients; IP = Premorbidly Impaired Patients; PC = Preserved Controls;  
Post-hoc comparisons were Bonferroni-corrected. 
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Table 2.  
 
Clinical Characteristics of Patients 
 
 
Variable             PP 
           (n = 29) 
 
       DP 
      (n = 14) 
 
       IP  
   (n = 14) 
 
     F   p Contrasts    
PANSS General† 40.7 (9.1) 41.1 (5.5) 44.6 (6.8) F2, 54 = 1.25 n.s.  
PANSS Positive† 
PANSS Negative† 
Anergia† 
Thought Disturbance† 
Activation† 
Paranoid† 
Depression† 
Schizoaffective 
Inpatients 
Duration of Illness 
 
 
41.7 (8.5) 
37.5 (7.5) 
42.6 (9.7) 
41.7 (7.9) 
43.3 (8.2) 
43.9 (7.5) 
50.7 (11.8) 
15 (52%) 
3 (10%) 
14.9 (10.5) 
 
 
40.9 (4.8) 
 
40.2 (7.6) 
 
46.1 (11.6) 
 
40.3 (6.7) 
 
44.2 (7.5) 
 
44.2 (5.6) 
 
50.5 (12.6) 
 
6 (43%) 
 
3 (21%) 
 
17.0 (8.5) 
 
 
 
 
43.8 (8.1) 
 
39.4 (4.5) 
 
43.8 (8.9) 
 
45.9 (8.9) 
 
45.1 (6.9) 
 
45.8 (7.2) 
 
54.2 (11.9) 
 
4 (29%) 
 
2 (14%) 
 
21.1 (13.4) 
 
 
 
 
F2, 54 = 3.67 
 
F2, 54 = 0.87 
 
F2, 54 = 0.60 
 
F2, 54 = 2.02 
 
F2, 54 = 0.25 
 
F2, 54 = 0.36 
 
F2, 54 = 0.47 
 
χ2 = 2.06 
 
χ2 = 0.96 
 
F2, 70 = 3.28 
 
 
 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
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Atypical Meds 
Antidepressants 
Anxiolytics 
Lithium  
Anti-Parkinson 
 
27 (93%) 
14 (48%) 
8 (28%) 
5 (17%) 
4 (14%) 
 
 
11 (79%) 
 
4 (29%) 
 
5 (36%) 
 
0 
 
2 (14%) 
 
 
11 (79%) 
 
2 (14%) 
 
3 (21%) 
 
2 (14%) 
 
2 (14%) 
 
 
χ2 = 6.97 
 
χ2 = 6.97 
 
χ2 = 0.71 
 
χ2 = 2.68 
 
χ2 = 0.00 
 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
    
Note: PP = Preserved Patients; DP = Deteriorated Patients; IP = Premorbidly Impaired Patients; PC = Preserved Controls; PANSS = 
Positive and Negative Syndrome Scale; † = T-scores; Post-hoc comparisons were Bonferroni-corrected 
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Table 3.  
 
Cognitive Characteristics of Schizophrenia and Healthy Participant Groups 
 
 
Variable PP 
(n = 29) 
 
DP 
(n = 14) 
 
IP  
(n = 14) 
 
PC  
(n = 36) 
F3, 89   p Contrasts    
Reading IQ  100.5 (5.8) 89.2 (10.6) 79.6 (7.6) 103.3 (6.9) 42.14 <.001 DP, IP < PP, PC; 
IP < DP 
WASI IQ 
MCCB†  
117.1 (5.7) 
 
71.2 (10.2) 77.9 (5.7) 116.9 (9.3) 184.27 <.001 DP, IP < PP, PC  
     PS 39.9 (8.6) 27.4 (11.1) 28.7 (11.8) 51.1 (10.0) 27.88 <.001 PP, DP, IP < PC;  
DP, IP < PP 
     Att./Vig. 43.5 (9.7) 26.1 (12.9) 28.5 (11.0) 50.1 (9.7) 25.96 <.001 DP, IP < PP, PC 
     WM 47.1 (8.0) 27.6 (11.3) 29.4 (8.6) 50.1 (8.2) 35.90 <.001 DP, IP < PP, PC;  
 
     Verbal 43.9 (8.2) 31.2 (6.4) 31.1 (4.2) 50.0 (9.0) 30.82 <.001 PP, DP, IP < PC;  
DP, IP < PP 
     Visual 41.8 (9.7) 27.4 (10.5) 25.4 (7.5) 45.5 (7.4) 27.07 <.001 DP, IP < PP, PC 
     Reason/PS 44.0 (9.4) 36.7 (7.6) 37.4 (7.6) 54.3 (8.5) 22.05 <.001 PP, DP, IP < PC 
     Social 
     Composite 
45.7 (10.0) 
 
39.9 (8.6) 
32.8 (11.3) 
 
17.9 (11.2) 
36.0 (11.8) 
 
19.5 (7.5) 
49.7 (11.3) 
 
49.9 (7.8) 
10.78 
 
70.31 
<.001 
 
<.001 
DP, IP < PP, PC  
 
PP, DP, IP < PC;  
DP, IP < PP 
Beads Test 10.0 (4.0) 
 
5.9 (5.2) 
 
7.0 (5.4) 9.6 (3.7) 4.15 .008 DP < PP, PC 
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IPSAQ 
Faux Pas 
6.7 (3.8) 
 
46.7 (5.8) 
4.3 (2.9) 
 
28.6 (14.4) 
6.4 (3.7) 
33.9 (13.9) 
6.2 (2.9) 
49.9 (8.6) 
1.75 
20.90 
n.s. 
<.001 
 
 
DP, IP < PP, PC  
Reading the Mind  25.5 (3.3) 18.8 (5.1) 18.2 (3.6)     28.1 (3.0) 39.26 <.001        PP, DP, IP < PC; 
          DP, IP < PP 
Note: PP = Preserved Patients; DP = Deteriorated Patients; IP = Premorbidly Impaired Patients; PC = Preserved Controls; WRAT3 = 
Wide Range Achievement Test 3rd edition; WASI= Wechsler Abbreviated Scale of Intelligence; MCCB= MATRICS (Measurement 
and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery; PS = Processing Speed; Att./Vig. = 
Attention/Vigilance; WM = Working Memory; Verbal = Verbal Learning; Visual = Visual Learning; Reason/PS = Reasoning/Problem 
Solving; Social = Social Cognition; IPSAQ = Internal, Personal and Situational Attributions Questionnaire, number of external 
personal attributions to negative social situations; Faux Pas = Faux Pas Recognition Test; Reading the Mind = Reading the Mind in 
the Eyes Test; † = T-scores; Post-hoc comparisons were Bonferroni-corrected 
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Table 4. Cortical Thickness in Schizophrenia and Healthy Participant Groups 
 
Variable PP 
(n = 29) 
 
DP 
(n = 14) 
 
IP  
(n = 14) 
 
PC  
(n = 36) 
F3, 87   p Contrasts    
RH superior temporal sulcus  2.43 (0.22) 2.55 (0.20) 2.38 (0.20) 2.60 (0.21) 5.67 .001 PP, IP < PC 
 
LH fusiform gyrus 
RH fusiform gyrus 
2.58 (0.14) 
2.60 (0.19) 
2.65 (0.19) 
 
2.65 (0.18) 
2.54 (0.20) 
 
2.54 (0.16) 
2.73 (0.16) 
 
2.71 (0.19) 
6.38 
 
3.39 
.001 
 
.022 
PP, IP < PC 
 
IP < PC 
LH middle temporal gyrus 
RH middle temporal gyrus 
LH inferior parietal lobule 
RH inferior parietal lobule 
2.70 (0.20) 
2.75 (0.18) 
2.42 (0.14) 
2.47 (0.13) 
2.84 (0.24) 
2.86 (0.21) 
2.47 (0.19) 
2.50 (0.20) 
2.76 (0.14) 
2.75 (0.14) 
2.43 (0.15) 
2.44 (0.20) 
2.88 (0.17) 
2.91 (0.17) 
2.53 (0.16) 
2.58 (0.15) 
5.09 
5.76 
3.25 
4.04 
.003 
.001 
.026 
.010 
PP < PC 
 
PP, IP < PC 
 
PP < PC 
 
PP, IP < PC 
LH supramarginal gyrus 
RH supramarginal gyrus 
2.48 (0.14) 
2.50 (0.14) 
2.55 (0.18) 
2.59 (0.15) 
2.48 (0.15) 
2.53 (0.16) 
2.58 (0.14) 
2.64 (0.16) 
3.28 
4.99 
.025 
.003 
PP < PC 
 
PP < PC 
 
RH precuneus 
RH frontal pole 
2.33 (0.14) 
 
2.56 (0.29) 
2.37 (0.17) 
 
2.65 (0.36) 
2.29 (0.15) 
 
2.58 (0.24) 
2.43 (0.18) 
 
2.80 (0.31) 
3.32 
 
3.93 
.024 
 
.011 
IP < PC 
 
PP < PC 
 
LH lateral orbitofrontal cortex 2.53 (0.12) 2.67 (0.16) 2.54 (0.14) 2.58 (0.15) 3.59 .017  DP < PP 
LH pars triangularis 2.35 (0.19) 2.52 (0.19) 2.33 (0.11) 2.45 (0.16) 4.63 .005 DP < PP; IP < DP 
 
Note: PP = Preserved Patients; DP = Deteriorated Patients; IP = Premorbidly Impaired Patients; PC = Preserved Controls; Post-hoc 
comparisons were Bonferroni-corrected 
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Figure 1. T-score profiles for patient and control groups on the Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) domains 
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Figure 2. 
Cortical thickness difference maps between control and schizophrenia groups (p values are 
calculated as -log10p) 
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Figure 3. 
Cortical thickness difference maps between control participants and preserved schizophrenia 
patients (p values are calculated as -log10p) 
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Figure 4. 
Cortical thickness difference maps between controls and premorbidly impaired schizophrenia 
patients (p values are calculated as -log10p and set at an uncorrected threshold of p=0.05) 
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Figure 5. 
Cortical thickness difference maps between deteriorated and premorbidly impaired schizophrenia 
patients (p values are calculated as -log10p and set at an uncorrected threshold of p=0.05) 
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